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ABSTRACT 
 Hot melt extrusion (HME) was evaluated as a processing technology for the manufacture 
of immediate as well as controlled release formulations for oral delivery of two model 
compounds. For immediate release applications lower molecular weight grades of 
Hydroxypropyl cellulose polymers, EF and ELF, were utilized as carrier matrices to form solid 
solutions of a poorly soluble compound, Ketoprofen (KPR). Thermal characterization techniques 
were used to confirm thermal stability, miscibility and setting up processing conditions for 
extrusion. Extruded matrices were pelletized to be filled into pellets or further milled and 
compressed into tablets. Pellets exhibited a carrier dependent release with ELF matrices 
releasing the drug at a faster rate than EF. Addition of Mannitol further enhanced the release 
with H4 formulation constituting KPR:MNT:ELF in a 1:1:1, releasing 88.5±1.5% drug in 1hr. 
Milled H4 matrices compressed into tablets exhibited rapid release with 90% drug release 
occurring in 15 min, similar to a marketed capsule formulation of the same dose. Stability studies 
performed utilizing mDSC, XRD and SEM studies confirmed the physical stability of the drug, 
post storage at 25°C/60%RH and 40°C/75%RH.  
Extrusion process also imparts significant physical transformations to the component 
systems which find utility in tabletting applications. Extruded matrices were compressed into 
tablets and tabletability profiles generated. Simultaneously tablet hardness evaluation was 
performed using conventional characterization techniques as well as using a texture analyzer. 
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HME tablets were more compressible and plastic nature in comparison to un-extruded tablets. 
ELF polymers exhibited better tabletting properties than EF. 
The ability of HME to homogenously mix polymers and drug was utilized to manufacture 
custom controlled release film formulations of a water soluble model drug. Polymer blends 
comprising Klucel™ EF (HPC), Eudragit® RSPO and POLYOX® N10 (PEO) were evaluated. 
Effect of polymer particle size on release was evaluated using in vitro release testing and Near 
Infrared chemical imaging techniques. Manufactured films exhibited controlled release for     
~24 hrs with HPC exhibiting a more pronounced effect than RSPO. A correlation of 90% was 
obtained between polymer concentration on fifty percent and eighty percent drug release, T50% 
and T80%, respectively, suggesting its applicability to bring about tailored release profiles. 
Extruded films remained physically and chemically stable for a period of three months at 
40°C/75%RH storage conditions. 
The ability of Cyclodextrin derivatives to enhance solubility of a poorly soluble drug, 
Clotrimazole was evaluated. Phase solubility studies were performed to assess the type of 
association between CT and 2-hydroxypropyl β Cyclodextrin. An AL type curve was obtained 
suggesting a 1:1 association, which was further confirmed utilizing DSC, FTIR, XRD, NMR and 
SEM analysis. Gels formulated from complex exhibited a complete release in 92 hrs whereas 
pure CT gels exhibited only 60% release in the same amount of time. Similar results were 
obtained with antifungal testing, with complexed gels having a more pronounced fungistatic 
action.  
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CHAPTER I 
INTRODUCTION 
High throughput screening techniques and combinatorial chemistry employed in the 
pharmaceutical industry has resulted in discovery of drug molecules with high potency and 
improved biological activity [1]. However, utilization of solvents such as DMSO and PEG for 
biological screening has resulted in compounds with decreased solubility entering development 
pipelines. Most of these compounds tend to be crystalline solids with high molecular weights, 
lipophillic character and have often been referred to as ‘brick dust’ compounds. Oral delivery of 
such compounds thus, becomes challenging and has led to emphasis in research on various 
solubilization techniques.   
Modified Noyes Whitney equation sums up the factors that influence dissolution rate of a 
drug in the dissolution media [2].  
  
  
 
        
 
             Equation 1-1.  
Where, dC/dt is the rate of dissolution, A is the surface area available for dissolution, D is 
the diffusion coefficient, Cs is the solubility of the compound in the dissolution media, C is the 
concentration of the drug in the media at time t, and h refers to the thickness of the diffusion 
layer of the dissolving drug. Dissolution is an extrinsic property and can be altered, - by 
increasing the surface area, increase wettability by the addition of hydrophilic polymers, 
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increasing diffusivity and/or by decreasing the thickness of diffusion layer. Solid dispersions, 
Complexation, Co-crystals, Lipid delivery systems primarily employ these principles in 
enhancing dissolution and bioavailability of poorly soluble compounds [3]. Solubility of a drug 
is an intrinsic property and can only be altered chemically via formation of salts or prodrugs. 
Most of the poorly soluble drugs are crystalline solids with well-defined molecular 
structures and are thermodynamically stable. Conversion of a crystalline compound to its 
amorphous form has been found to be useful in enhancing solubility of such compounds [4]. 
Amorphous forms have a higher Gibbs free energy and lack long range molecular order, unlike 
crystalline compounds, which results in an increase in dissolution rate [5]. However, high-energy 
forms tend to revert to their more stable, low energy crystalline forms during processing or on 
storage. Successful utilization of this technology thus, requires stabilization and prevention of 
form conversion.  
Solid dispersions and solid solutions that employ a carrier matrix, have been found to be 
immensely useful in enhancing solubility by increasing surface area of the drug and 
simultaneously stabilizing the amorphous form. Another technique that has attained importance 
in the last ten years include co-crystals [5] and forming inclusion complexes utilizing CD’s [6]. 
Most of these CD’s are labeled as safe excipients and have been utilized in as many as 40 oral 
and parental formulations. Lipid based Self-emulsifying drug delivery systems (SEDDS) are 
isotropic mixtures that readily form an emulsion in the lumen and result in increased solubility. 
They also aid in absorption due to enhanced lymphatic uptake of poorly soluble drugs [7-9]. 
Most of the solubilization techniques either involve utilization of organic solvents or are multiple 
step batch processes that significantly increase processing time. Techniques such as 
complexation and co-crystals also suffer from problems associated with scale up. 
3 
 
1.1. Solid Dispersions and Solid Solutions 
Solid dispersions (SD) have been defined by Chiou and Riegelman as “ the dispersion of one 
or more ingredients in an inert carrier or matrix, where the active ingredients could exist in 
finely crystalline, solubilized or amorphous state” [10]. Carriers are typically long chain 
polymers with better aqueous solubility than the drug molecule and selected based upon their 
ability to disperse or solubilize the drug.  Depending upon the extent of solubilization of drug in 
the polymer, SD’s can be classified as eutectics or solid solutions [11]. Eutectic SD’s refer to 
matrices wherein the drug is distributed in a microcrystalline state in a polymer matrix. Solid 
solutions and solid dispersions refer to a molecular distribution of component systems where 
one system cannot be discerned from the other. A lack of crystalline character of the drug in the 
matrix is often referred to as a solid solution.  
Techniques such as Differential scanning calorimetry (DSC), X-ray diffraction (XRD), 
Polarized light microscope (PLM) and Infrared spectroscopy are commonly utilized to identify 
the type of solid dispersion. DSC and XRD studies also enable one to establish miscibility as 
well as solubility of the drug in the polymer matrix. Analytical techniques currently available 
fail to detect low levels of crystallinity that differentiate solid dispersions from solid solutions 
and hence the terms are used interchangeably. Solid solutions, in which the polymer and drug 
exist in an amorphous form, are the most commonly employed to enhance solubility of poorly 
soluble drugs. Long chain polymers such as Hydroxypropyl cellulose (HPC), Polyvinyl 
pyrrolidone (PVP) or Polyethylene glycols (PEG) are most commonly utilized as they exist in 
an amorphous form and are also hydrophilic in nature. Also, these polymers can be synthesized 
with wide range of molecular weights and can be utilized to achieve tailored release. 
Amorphous form of the drug in SD’s tend to recrystallize on storage and these polymers can 
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address such issues by preventing such transformations. Polymers with high glass transitions 
temperatures prevent recrystallization by stearic hindrance whereas those with functional groups 
might form hydrogen bonds preventing recrystallization. 
1.1.1. Advantages and Disadvantages Solid dispersions   
Solid dispersion is a proven, viable technology that has been used extensively for 
solubility enhancement of poorly soluble drug due to its inherent advantages [11]. Increase in 
solubility from SD’s has been attributed to increased surface area and wettability due to 
hydrophilic polymers which results in a decrease in thickness of the diffusion layer. The 
processing steps involved in formation of SD’s result in physico-chemical transformations that 
favor increased solubility. Conversion to a high energy amorphous form, being one of them, can 
also impart enhancement in solubility and bioavailability [12, 13]. In certain cases conversion of 
amorphous drug to microcrystals in SD’s was found to have better dissolution than the pure drug 
[14].  
Solid dispersions are manufactured using hydrophilic carriers which, owing to their high 
solubility, might leach out, resulting in precipitation of the drug. Also, most of the SD’s employ 
amorphous form of drugs which tend to revert back to more stable, crystalline forms, thus 
affecting release profiles. Hydrophilic polymers tend to absorb moisture on storage which allows 
for an increase in free volume, and subsequently, crystallization. Also, it is in the best interest of 
oral formulation development, that there exists high solubility of drug in the polymer matrix, as 
it results in smaller dosage forms. Exceeding this solubility limit may result in phase separation 
or crystallization. In Ritonavir SD’s, it was observed that an increase in drug loading resulted in 
a corresponding faster in vitro release, but did not reflect in in vivo testing [15]. This difference 
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was attributed to phase separation occurring at higher drug loading. Rapid release occurring due 
to SD’s of atorvastatin resulted in a super saturated solution from which the drug precipitated 
out, decreasing the bioavailability [16].  
1.1.2. Manufacturing Methods 
One of the hurdles towards development of solid dispersion or a solid solution, as noted 
by Serajuddin include  – method of preparation, reproducibility, process scale up leading to 
manufacturing, and physico-chemical stability on storage [12]. Thus, a suitable carrier and a 
process that can manufacture a suitable matrix, aiding stability of SD’s, becomes a crucial step 
towards successful utilization of this technique. Many methods have been developed to 
manufacture solid dispersions notably - solvent evaporation [17], fusion method [18, 19], 
complexation, spray drying [20] and hot melt extrusion [21, 22].  
Solvent evaporation is the most common and simplest of the techniques used. Drug and 
polymer are solubilized in a common solvent, usually an organic solvent, and dried via tray, 
Rotovap or Vacuum drying, to form SD’s. Though, it is a feasible and simple technique for 
initial screening, it suffers from scale up issues. Spray drying process utilizes a similar principle 
and has been extensively used to form SD’s on a commercial scale. Spray drying has been in use 
in pharmaceutical industry for the manufacture of inhalation formulations and has already 
addressed many of the issues with scale up. This has accelerated it as an important technique for 
the manufacture of SD’s. Formulations obtained are spherical, free flowing and can be easily 
processed further. However, it suffers from the drawback that it is a solvent based batch process 
that requires both drug and polymers be soluble in a common solvent.  
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Research in Solubility enhancement has gained prominence in last ten years due to an 
increase in highly crystalline, poorly soluble drug compounds. Techniques such as HME and 
spray drying have been a ‘go to’ technology to form amorphous solid dispersions of these low 
soluble agents. With the advent of new polymers, problems such as phase separation, 
crystallization, precipitation and agglomeration have been duly addressed thus propelling 
efficient utilization of these techniques. 
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1.2. Hot Melt Extrusion 
Hot melt extrusion (HME) is a versatile processing technology that can be used for 
solubility enhancement, granulation and as a physico-chemical stability imparting system. Being 
a non-solvent process, HME has significant utility in manufacture of solid dispersions and solid 
solutions. The process involves melting or softening of drug/s and excipients in a heated barrel 
which are then pushed through a die, to yield extrudates of various shapes and sizes [23]. The 
intense mixing and shearing distributes the drug uniformly in a polymer matrix and depending 
upon the drug and polymer interactions, aid formation of a solid solution or a solid dispersion 
[24]. The heating process and the polymers further aid the conversion of a crystalline drug to an 
amorphous form, thus contributing towards increased surface area. The extrudates, as per 
requirement, can be further processed into pellets as multi-particulate systems, films or into 
tablets by milling and addition of tabletting excipients [25].  
Thermoplastic polymers that can withstand high temperatures and shear are exclusively 
used in HME to form solid dispersions or solid solutions. Processing aids can be added to further 
decrease the viscosity of the melted matrix [26], as pore formers or to impart physico-mechanical 
properties to the extruded matrix. Unlike other processes commonly employed in pharmaceutical 
industry, HME is a continuous process and can be scaled up easily. Being a process that is 
performed at high temperatures, the polymers and the drug have to meet the requirement of being 
thermoplastic, thermostable and withstand the shear exerted by the screws. 
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1.2.1. Types of Extrusion Process 
 Extrusion processing involves two different types of extrusion, referred to as dry 
extrusion and the other being wet extrusion. Wet extrusion, as the name suggests involves the 
use of solvents such as water or alcohols that are utilized to activate a binder, creating a wet 
mass. The mass is then extruded through a sieve to form spaghetti like strands that are 
spheronized to form pellets. Wet extrusion results in product that are uniform in nature and have 
a better finish due to ripening action of the excipients [27]. Also, this method is more suitable for 
drugs and excipients that are heat sensitive as there is less buildup of localized heat. Dry 
extrusion is a non-solvent process involving thermoplastic agents that melt at high temperatures 
to form homogenous matrices inside a hot melt extruder.       
1.2.2. Schematics and Components of a Hot Melt Extruder  
 Hot melt extrusion has been in use in plastics industry for a long period of time. Hence, 
most of the instrumentation and post processing equipment employ similar designs that have 
been adapted to accommodate pharmaceutical requirements. Essentially, a Hot melt extruder can 
be divided into sections such as feeding, heating, conveying, metering and die sections.  
Based on the conveying mechanism used, there are essentially two types of hot melt 
extruders. A ram extruder employs a piston as a conveying element. The material is fed into a 
heated barrel and allowed to melt before being pushed out by a positively displacing piston, that 
forces the material through a die plate [28]. Drawbacks with such an extruder include non-
uniform heat distribution, improper melting and a non-homogenous distribution of the 
components due to lack of mixing elements.  
9 
 
1.2.3. Screw based Extruder 
 Screw based extruders are most commonly utilized in pharmaceutical industry as it aids 
in more efficient mixing. As the name suggests these extruders utilize a screw that spans the 
entire length of the barrel, conveying material from feeding section to the discharge plate. 
Screws allows for feeding, conveying, blending and metering operations and also in pushing the 
material out through a die. Screw extruders allow for uniform melting and mixing of components 
and hence result in a more homogenously distributed extrudate. These extruders are primarily 
two types, single screw and twin screw extruders. Single screw extruders, as the name suggests, 
have a single screw element that rotates and mixes the components in a heated barrel. These 
extruders are able to handle immense pressure build up that can occur with viscous material, at 
the same time maintaining consistent pressure. Screw with diameter less than 18mm, as they 
taper towards the discharge end, tend to lose their discharge capacity. Hence, these extruders are 
designed with a motor on the discharge end to increase discharge capacity [29]. The components 
of a screw based extruder include – drive motor, barrel, and screw elements.  
1.2.3.1. Driving motor 
 Driving motor is the heart of the extrusion system providing the necessary torque 
required to rotate the screws and convey the material. Process control parameters such as motor 
torque, amperes, and rotations per minute (rpm) are continuously monitored to evaluate success 
and feasibility of HME process. If needed, suitable processing aids can be added to improve the 
extrusion process [30, 31].  Residence time is the amount of time material is inside a barrel and is 
directly related to motor speed. Thermally sensitive compounds undergo degradation on 
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continued exposure to heat and hence a lower residence time significantly decreases this 
possibility.  
1.2.3.2. Barrel 
Barrel of an extruder is designed to conduct heat and, be able to withstand the pressure 
and mechanical stress generated due to the rotating screws. Additionally, it should be easily 
accessible to be cleaned at the end of an extrusion process. Depending upon the manufacturer, 
two types of barrels are primarily used. A monoblock design constitutes a single block of steel 
with access for feeders, screw elements and temperature controlling units (Ex. Leistritz
®
 
Nano18). Second type of barrel unit involves a clam-shell design that allows for separation of 
upper and lower sections. The sections are held in place by a series of screws with heating units 
placed in the bottom section. Extruders manufactured by Thermo Scientific
®
, Brabender
®
 are 
based on this design. Clam shell design allows for ease of access in cleaning the screws and the 
barrel but also suffers from a possibility of molten material leaking out, if not tightened very 
well. Monoblock design circumvents this disadvantage but suffers from the fact that screws and 
barrels cannot be easily taken out for cleaning purposes when viscous polymer is used. 
Temperature of the barrel is controlled by heating elements and thermocouples. Modular design 
based barrels consists of multiple zones which can be accurately maintained at different 
temperatures as required. This also allows for flexibility to use different temperature profiles 
such as maintaining the zone closes to the feeding at lower temperature and the die at a higher 
temperature to aid extrusion by decreasing viscosity. Some extruders also have a built in cooling 
mechanism near the feeding section to prevent sticking of material. The barrel of an extruder can 
be divided into sections – feeding zone, conveying zone, compression zone, metering zone and 
discharge zone as shown in the figure 1-1.    
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Figure: 1-1. Component sections of a Single Screw Hot Melt Extruder 
 
1.2.3.3. Screw Elements 
Screw design plays an important role in extruder design and it can be altered to address 
specific needs of the formulation. Figure 1-2, represents a cross-section of a screw in a barrel. 
The channel depth is the distance between the screw and the barrel. This is widest at the feeding 
zone to allow material to be added and is narrowest at the compression zone. The compression 
zone of an extruder has a decreased channel depth allowing for the entrapped air to be squeezed 
out as well as to allow for thorough mixing [32]. Channel width is the space between each 
individual thread on a screw. These are spaced out in the feeding section to allow for more 
material to fall and decreases in the compression zone. Metering zone has the screw elements 
placed with uniform channel width to allow for uniform output.  
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Figure: 1- 2. Schematics of an Extruder Screw [adapted from Ref. [24]] 
  
Current HME screws employ a modular design that allows for elements that can be 
interchanged as per need. Screw elements thus, can be altered to achieve increased shearing or 
conveying, as required by intended application. Figure 1-3 refers to different types of screw 
configurations that can be utilized [33]. Conveying elements are the least aggressive and as the 
name suggests, are used to convey the material forward. They are usually arranged next to 
feeding zones and might also have a wider channel width. Dispersive elements allow for 
maximum shear and aggressive mixing, and depend upon conveying elements to move the 
material forward. Dhumal et al observed that formation of co-crystals was maximum when more 
dispersive elements were added to screw configuration as it allowed for intense shearing [33].  
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Figure: 1- 3. Types of Screw elements [adapted from Ref. [33]] 
 
 
1.2.3.4. Twin screw extruders (TSE)  
TSE’s employ two screw elements that either rotate in opposite direction (counter 
rotating) or in same direction (co-rotating). These extruders allow for easier feeding, better 
mixing and dispersion of component systems, de volatilization, reduced heat generation and a 
shorter residence time. TSE’s are the most commonly utilized extruders in the pharmaceutical 
industry and the choice to use a counter or co-rotating extruders depends upon the intended 
application. Counter rotating TSE’s allow for intense mixing, high shear and in dispersing 
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materials more uniformly. The drawbacks of using such a system include high air entrapment 
and generation of excessive heat and stress, which might result in product degradation. Also, 
counter rotating screws experience excessive wear and tear due to outward push of the material 
and cannot be operated at high speeds. Co-rotating extruders allow for high speeds and 
significantly bring down the wear and tear on the motor and screws. These screws are typically 
intermeshing and hence are self-cleaning, allowing for a reduction in localized heat generation.  
1.2.3.5. Discharge and Post Processing Equipment   
Die is the final component of an extrusion system and is used to shape the extrudate 
material. It consists of a perforated or shaped opening in a steel block and is attached to the distal 
end of an extruder.  Die also holds ports for pressure transducers, thermocouples, and probes that 
aid in analytical analysis of the extrusion process and can be used as a process analytical tool 
[34, 35]. Depending upon the intended final dosage form, different die are utilized to shape the 
extrudate material. A flex lip die allows for manufacture of films for transmucosal, transdermal 
or transungal applications [36, 37]. A chill roll is utilized to cool the film and to maintain 
uniform thickness by passing it in between spaced rolls. Cylindrical die allows for extrudate rods 
that can be further processed into pellets, mini matrices or, milled for tabletting applications. 
Temperature control of die is of crucial importance as it aids in managing the pressure 
and material characteristics post extrusion. Highly viscous material undergoes compression when 
pushed through the die resulting in a decrease in porosity. Viscoelastic polymers such as HPC 
and PEO undergo die swelling on exiting the die. Increasing the temperatures, hence, reduce the 
viscosity and aids extrusion of such polymers. Post processing equipment is essentially utilized 
to cool the extrudates or in certain cases to further shape the extrudates, as in injection molding 
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applications. Die with a built in rotating knife has been utilized to cut extrudates and form 
spheres through a spheronization process. In certain special applications such as granulation, 
extruders are operated without a die to prevent compression of the material. Vasanthavada et al 
evaluated applications of HME as a granulation technique by operating the extruder without a die 
plate to form granules and compressed them into tablets [38]. 
1.2.4. Carriers and Processing Aids 
HME process involves intimate mixing of carrier components and active ingredients to 
form a homogenous system that stays stable during the intended period of storage. Carriers not 
only aid in formation of a solid dispersion of the amorphous drug, but, also aid in maintaining 
the high energy state. These carrier molecules have to meet the requirement of being thermally 
stable and withstand the shear being exerted by the screws without degrading. Thermoplastic 
polymers that can withstand high temperatures are exclusively utilized in HME to form solid 
dispersions or solid solutions. Processing aids can further be added to decrease viscosity of the 
melted matrix, increase stability, as pore formers or to impart physico-mechanical properties to 
the extruded matrix.  
Being a hot process, thermo stability and plasticity of all components is critical and 
various analytical techniques are utilized the asses the same. Initial screening studies typically 
involve thermal characterization techniques such as Thermo-gravimetric analysis (TGA), and 
Differential scanning colorimetry (DSC) [39-44] and in some cases, may also involve Gel 
chromatography studies [45, 46] for chemical stability assessment of polymers.  
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1.2.4.1. Carrier materials  
Carrier materials and processing aids are the most important components of an extrusion 
system. Depending upon the intended application of the final dosage form, many polymeric and 
non-polymeric material have been evaluated for HME applications. Most of the polymers 
utilized are high molecular weight compounds and are either semi crystalline or crystalline in 
nature. 
Polyethylene oxide (PEO) polymers are free flowing, semi crystalline polymers, 
synthesized by heterogeneous catalytic polymerization of ethylene oxide monomers. These 
polymers have a melting range between 57-73°C and are available in a wide range of molecular 
weights ranging from 100 to 800 Kilo Daltons. PEO polymers are water soluble in all ratios, with 
higher molecular weight polymers requiring longer time to dissolve. Due to their thermoplastic 
behavior, PEO polymers have been utilized for various applications in HME such as immediate 
to controlled release, and due to plastic nature, as plasticizers [45].  However, these polymers 
undergo oxidative degradation at high temperatures and hence require antioxidants.  
Cellulose based polymers are obtained by alkylation of naturally occurring celluloses and 
have a wide applicability in pharmaceutical industry. Polymers with a wide variety of viscosities 
and solubilities can be synthesized by altering the extent of substitution. Cellulose ethers such as 
Hydroxyethyl cellulose (HEC) and Hydroxypropyl cellulose (HPC) have been utilized in HME 
owing to their stability and release characteristics [36, 37, 47, 48]. HPC is a nonionic, water 
soluble, thermoplastic cellulosic ether and has been extensively utilized due to its organic, as 
well as aqueous solubility, and surface activity [49]. HPC polymers have a fixed molar 
substitution and hence molecular weight is altered by controlling degree of polymerization. 
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These polymers undergo dissolution by swelling and erosion mechanism which is molecular 
weight dependent [50]. Klucel™ HPC EF and ELF hydroxypropylcellulose are nonionic, 
thermoplastic, and lower molecular weight polymers with a molecular weight of approximately 
80,000 and 60,000 Daltons, respectively. HPC polymers have been used previously to control 
drug release from hot melt extruded films [51, 52] and as a granulation binders [53].  
Hydroxypropylmethyl cellulose is a partly o-methylated and o-(2-hydroxypropylated) 
non-ionic cellulose ether typically utilized as a release modifying agents. HPMC has high glass 
transition temperature and hence require a plasticizer for HME applications. Repka et al 
characterized blends of Hydroxypropyl methyl cellulose plasticized using Hydroxypropyl 
cellulose films manufactured via HME [52]. Depending upon acetyl and succinoyl substitution 
on HPMC, HPMC-AS polymers with varied pH sensitivity have been synthesized. These 
polymers do not dissolve in gastric fluid but swell up in gastric media and exhibit diffusion 
controlled release of the drug [54, 55]. Ethyl cellulose polymers are water insoluble, 
thermoplastic, compressible polymers and have been evaluated as control release agents in HME 
[30, 56].   
Polymethacrylate polymers are synthesized by varying ratios of dimethylaminoethyl 
methacrylate, methacrylic acid and methacrylic acid esters. These polymers have been utilized in 
HME for wide variety of applications ranging from controlled release [43], immediate release 
[57, 58], enteric coating [59], as well as for taste masking [60] applications. Polyvinyl 
pyrrolidone (PVP) polymers are another class of synthetic polymers consisting of linear chains 
of 1-vinyl-2-pyrolidone,that have been utilized as carriers in HME. Similar to HPC, PVP 
polymers are manufactured by varying the degree of polymerization resulting in compounds with 
different molecular weights. PVP polymers are highly water soluble and have been known to 
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maintain physical and chemical state of the drug [61]. Kollidon VA-64, a copolymer of 
vinylactetate and PVP, is an excellent solubulizer and has been utilized to increase 
bioavailability of poorly soluble drugs [62]. Most of the solid dispersions utilize an amorphous 
form of the drug, which being a high energy form, tends to recrystallize back. VA-64 in addition 
to forming solid dispersions, has been found to maintain the amorphous form, preventing its 
recrystallization [63, 64]. 
In addition, other non-polymeric materials have been explored in HME as a carrier 
material, fillers or to modify release profiles. Bialleck et al utilized starch to manufacture pellets 
with decreased porosity, a narrower particle size distribution, improved dissolution and 
compared them to pellets manufactured using conventional extrusion-spheronization processes  
[65]. Liu et al utilized waxes as thermal binders which also aided in retarding the release in 
extrudates [66]. They also evaluated excipients such as microcrystalline cellulose and lactose as 
fillers. Sugars such as Isomalt [67], Erythritol [68] and Mannitol [69] have been explored in 
HME to form solid dispersions and effect solubility. Isomalt when coextruded with paracetamol 
was found to enhance tabletting properties due to conversion to an  amorphous form [70]. 
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Table: 1- 1. Carriers used to prepare hot-melt extruded dosage forms 
Chemical Name Trade Name Tg (C) Tm (C) 
Ammonio methacrylate copolymer Eudragit
®
 RS/RL 64 -- 
Poly(dimethylaminoethylmethacrylate-
co-methacrylic esters) 
Eudragit
®
 E 50 -- 
Poly(methacrylic acid-co-methyl 
methacrylate) 1:2 
Eudragit
®
 S/L 160 -- 
Cellulose Acetate Phthalate -- 165 192 
Poly(vinyl pyrrolidone) Kollidon
®
 90-156 -- 
Poly(vinyl acetate) Sentry
®
 plus 35-40 -- 
Hydroxypropyl Methylcellulose 
Phthalate 
-- 137 150 
Polyvinyl pyrrolidone-co-vinyl acetate Kollidon
®
 VA64 101 -- 
Polyvinyl caprolactam-polyvinyl acetate-
polyethylene glycol graft copolymer 
Soluplus
®
 70 -- 
Hydroxypropyl Methylcellulose (HPMC) Methocel
®
, 
Benecel
®
 
160-210 -- 
HPMC Acetate Succinate Aqoat-AS
®
 ~ 120 -- 
Ethyl cellulose Ethocel® 
Aqualon® EC 
130-133
o
C  
Hydroxypropyl Cellulose Klucel® Softens at 130
o
C  
Polyethylene Glycol Carbowax® -17
o
C  37-63
o
C 
Polyethylene Oxide PolyyOx® WSR -57 to -50
o
C 62-67
o
C 
Polymethacrylates Eudragit ® RSPM 
Eudragit ® E 
52
o
C , 40
o
C -- 
Carnuba Wax ---  81-86
o
C 
Glyceryl palmitostearate Precirol ATO 5
®
 ---- 52
 
-55
 o
C 
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1.2.4.2. Processing Aids 
 Extrusion is a mechanical process that involves mixing and blending operations brought 
about by rotating screw or screws. The torque exerted by the screws is dependent upon the 
viscosity of the melt and plasticizers help in reducing the torque on the motor. They also play an 
important role in improving physico-mechanical properties of the extruded dosage forms, 
imparting flexibility in certain cases. A decreased viscosity also aids in better processing 
conditions such as lower barrel temperatures, higher screw speeds and a decreased residence 
time which, overall helps in reducing energy consumption and increased efficiency of the 
extrusion process. For thermally sensitive compounds, a decrease in residence time can also 
mean improved stability due to less exposure to heat. Most of the HME polymers utilized are 
semicrystalline polymers with high glass transition (Tg) temperatures [59]. Plasticizers are able 
to decrease Tg and increase the polymeric free volume, thereby decreasing the required 
processing conditions [71]. Shorter chain length polymers orient themselves between longer 
polymer chains allowing for increased polymer spacing and weakened polymeric intermolecular 
interactions. These compounds also allow polymeric materials to change configuration, thus 
allowing them to slide over each other upon exertion of stress. Lower molecular weight grades of 
polymers such as, polyethylene glycols [26, 72] and polyethylene oxides have been extensively 
used as plasticizers. Low melting, small molecule drugs, when extruded with viscous polymers 
have been observed to act as a plasticizers and aided the extrusion process [26, 73, 74]. 
Triethyl citrate (TEC) was utilized by Bruce et al to plasticize Eudragit
®
 S prior to 
extrusion, utilizing a granulation method, as TEC is a liquid [59]. It was found that addition of 
TEC decreased the Tg due to reduced intermolecular interactions among the polymer chains. 
TEC has been utilized as a plasticizer with other acrylic polymers and to improve mechanical 
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properties [43, 75, 76]. Absorbed moisture was found to have a plasticization effect on extruded 
HPC films and thereby contributed towards increased ductility [37]. Repka et al reported 
advantages of Vitamin E TPGS as a plasticizer [72]. Andrews et al reported that extruded 
material, as they are being pushed through the die undergo a loss in porosity [41]. Plasticizers 
may affect the product on storage due to volatilization over a period of time, effecting release 
and mechanical integrity. Repka et al observed in extruded films of Hydrocortisone (HC), in 
which HC acted as a plasticizer, an increase in brittleness corresponded to a decrease in HC 
content on storage [26]. Transient or temporary plasticizers, such as carbon dioxide or water 
have been explored to counter this disadvantage. Verreck et al reported that pressurized or 
supercritical Carbon dioxide was found to decrease the Tg of semicrystalline polymers as well 
act as a foaming agent, thereby increasing porosity of the extruded material [77-80].  Plasticizers 
also play a very critical role in development of films for transmucosal [81] and transdermal 
applications as they aid in maintaining required film flexibility. Cilurzo observed that films with 
rapid release could be manufactured utilizing Maltodextrins in combination with film forming 
polymers [82]. They evaluated plasticizers based on flexibility, tensile strength, and adhesiveness 
of films and their effect on release. Citric acid has been found to be a good plasticizer as well as 
a release modifying agent by altering the micro environmental pH [42]. 
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1.2.5. Pharmaceutical Applications of Hot Melt Extrusion  
 HME processing has gained prominence in recent times due to its applicability as a 
solubility enhancing technique for poorly soluble drugs [64]. With appropriate selection of 
polymers, stable solid dispersions of poorly soluble drugs can be manufactured in a one-step, 
continuous process. Formulations comprising, tablets, capsules, films or mini-matrices can be 
manufactured with slight modification to extruder and addition of post processing equipment. He 
et al evaluated the advantages of Eudragit E100 and PVP-VA copolymer in enhancing solubility, 
and thereby, bioavailability of Fenofibrate [14]. HME was able to form microcrystals of the drug 
in a hydrophilic matrix, which resulted in faster dissolution due to increased surface area. 
Amorphous Nimodipine solid dispersions manufactured utilizing Kollidon polymers exhibited 
enhanced solubility and stability on storage [39]. HME has also been utilized to form complexes 
of β-cyclodextrin and a poorly soluble drug to enhance its solubility. The technique was found to 
be faster, and an efficient method for the manufacture of complexes [83]. SD’s commonly 
employ amorphous form of the drug to enhance solubility, however they suffer from, form 
reversion on storage. Thommes et al utilized HME to address these issues by forming nano 
crystalline SD’s of a poorly soluble drug using a crystalline excipient, which exhibited a faster 
release and also remained stable [84].    
Most of the polymers currently in use in pharmaceutical industry for modified release 
applications can be utilized in HME to achieve targeted release profiles. HPC polymers marketed 
under the name Klucel™, constitute polymers with a wide variety of molecular weights and have 
been used extensively to modify release of soluble drugs [51, 81]. Hot melt extrusion process 
allows for a wide selection of polymers that can be used to tailor profiles from immediate to 
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controlled release [44, 85, 86] and in some cases, can be utilized for prolonged release 
applications. 
Special Applications 
Extruded films, by the use of appropriate post-processing equipment, have been used to 
shape formulations for transungal [48], transdermal [87-89], transmucosal, and other 
biodegradable [90] applications. With the appropriate use of polymer- drug combination and post 
processing equipment, HME can be utilized to manufacture films and implants, with desired 
release and shape. HME manufactured injection molded implants exhibit uniform mixing and 
distribution of components and aid in achieving desired release profile. Johnson et al were able 
to manufacture dual drug segmented implants utilizing HME which was otherwise, not feasible 
through conventional techniques [91]. Cheng et al utilized HME to manufacture implants for 
prolonged release of Praziquantel, an anthelminthic drug, from Polycaprolactone matrices [92]. 
Other special applications include, formation of co-crystals, floating tablets for gastro 
retentive delivery [93] and taste masking of bitter agents. Manufacture of Co-crystals is a tedious 
process that involves either solvent based methods or intense mixing operations. Dhumal et al 
were able to utilize a twin screw extruder to manufacture co-crystals of Ibuprofen and 
Nicotanimide. Screw design with more aggressive mixing elements, rotating at low speeds 
allowed for a maximum yield of co-crystals [33]. HME has also been utilized to form solid 
dispersions of bitter drugs using appropriate polymers to mask their taste [94]. With the advent 
of new polymers and plasticizers, processing temperatures have dropped significantly allowing 
for extrusion of heat sensitive material and also bioactives such as lysozyme [95]. 
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1.3. Cyclodextrins   
Cyclodextrins are cyclic oligosaccharides consisting of six α-Cyclodextrin, seven β-
cyclodextrin, eight ɣ- cyclodextrin or more glucopyranose units linked by α-(1,4) bonds. The 
glucopyranose units, which exist in a chair like conformation, take the shape of a truncated cone 
or torus in CD’s. Most of the derivatives currently in use, derive their origin from three types of 
CD’s - α, β, and ɣ, and are considered to be parent CD’s. These cyclodextrins exhibit decreased 
solubility due to stronger binding and crystalline characters. β-cyclodextrin molecules form 
hydrogen bonds that prevent their solubilization in solutions.  
Modification of CD’s utilizing cellulosic derivatives such as, Carboxymethyl cellulose 
and Hydroxypropyl methyl cellulose has resulted in compounds with increased solubility. It was 
observed that methylation of the hydroxyl groups on the outer ring resulted in a dramatic 
increase in solubility of β CD’s. Several derivatives were later synthesized that include 2-
hydroxy propyl derivatives of β CD (HPbCD) and γ CD (HPgCD) and Sulfobutylether 
derivatives of βCD (SBbCD). The solubility enhancement has also been attributed to the 
conversion of crystalline CD’s to an amorphous mixture of isomeric derivatives [96]. The 
reaction conditions employed, significantly affect the isomerization process and hence, CD 
derivatives obtained from different manufacturers, or even from different batches differ slightly. 
Complete substitution results in decreased solubility due to a drop in number of possible isomers. 
Degree of substitution also affects the access of the CD cavity to the host molecule. However, 
continued research in this area has resulted in many such derivatives being synthesized. Lack of 
toxicological data on these derivatives limit their use to industrial applications as the current, and 
time tested CD derivatives are able to satisfy the needs of pharmaceutical industry. Many of 
these CD’s are categorized as ‘Generally Regarded As Safe’ (GRASS) by the FDA and have also 
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been mentioned in the Pharmacopeias. Oral as well as parental formulations based on CD’s are 
already marketed in the Europe and USA. Modified CD’s such as 2-Hydroxypropyl- β-
cyclodextrin (HPbCD), Sulfobutylether β-CD are approved by regulatory agencies  and have 
been used in parental formulations at high concentrations [97]. Japanese Pharmaceutical Codex 
considers all the three α-, β - and γ- CD’s as safe and have been approved to be used as a food 
additives.  
1.3.1. Mechanism of Inclusion complex formation  
 CD’s are known to form inclusion complexes with wide variety of compounds ranging 
from solid, liquids and gases by molecular complexation [98]. X-ray studies performed on CD’s 
confirm presence of hydroxyl groups on outer edge, with apolar hydrogen’s and ether like 
oxygen’s in the inner core. This distribution results in formation of a hydrophilic outer surface 
and hydrophobic inner core. The presence of an inner cavity allows CD’s to form inclusion 
complexes. Though height of CD cavity remains the same, diameter of the cavity is dependent 
upon the number of glucose units. α-CD’s can thus accommodate small molecules whereas β-
CDs can accommodate aromatics and heterocyclic compounds [98].  
Complexes are formed by replacement of enthalpy rich water molecules from the CD 
cavity by a more hydrophobic guest molecule. There is apolar-apolar association that results in 
reduction of ring strain and hence, is the driving force to form complexes. These associations are 
non-covalent and in dynamic equilibrium with each other. Though complexes are formed 
rapidly, equilibrium takes longer time to be established as the guest molecules are held by weak 
Vander Waals forces. The lipophilic core of CD is made up of skeletal carbons and ethereal 
oxygens and this lipophilic microenvironment provides a suitable cavity in which drug molecules 
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can enter. The hydrophilic outer core lined with hydroxyl groups allow CD’s to form hydrogen 
bonding with solvents and hence result in increased solubility. Binding strength depends upon 
how close a fit is obtained between the guest and CD molecule. 
 
 
 
Figure: 1- 4. Cyclodextrins structure and Inclusion complex formation. Ref.[98] 
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1.3.2. Method of Manufacture of CD complexes 
Various methods have been described in the literature for the manufacture of complexes. 
Most of these methods utilize solvents in different proportions to either form a solution, slurry or 
a paste and may involve heating and mixing steps to speed up the process. Water is the solvent of 
choice as CD’s are most soluble and form complexes readily with poorly soluble drugs. 
However, additional solvents might be utilized to compensate for decreased aqueous solubility of 
poorly soluble drugs and such solutions then added to CD solution to form complexes. Addition 
of water also helps formation of complexes for higher molecular weight compounds such as oils, 
as it helps in preventing aggregation of oil molecules. Hot melt extrusion has also been utilized 
as a means to form complexes of a poorly soluble drug with Sulfobutyl ether β-cyclodextrin  and 
β-cyclodextrin [83]. HME has an advantage of being a continuous process, however, the shear 
generated may damage the structure of CDs. Commonly used complexation methods involve a 
solvent removal step at the end of process and techniques such as spray drying, tray drying are 
typically utilized [99]. Care must be taken during drying step as thermolabile drugs may degrade 
due to excess heat built up. Processes like lyophilization or freeze drying are typically employed 
for such compounds. Also these techniques convert the drug to an amorphous form thus further 
enhancing solubility [100]. 
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Complexation Efficiency 
Formation of complexes is a dynamic process that involves association and dissociation 
of formed complexes. Phase solubility analysis as described by Higuchi and Connors, is a widely 
utilized technique to determine complexation constants and the complexation process, as such 
[101]. Excess amount of drug is incorporated into vials containing CD solutions at successively 
increasing concentrations and allowed to equilibrate over a period of time. Slope is then 
calculated from the plot of molar concentration of drug dissolved to CD concentration. The 
stability constant (K) can then be calculated utilizing the following equation.  
  
     
           
                      Equation 1-2. 
Where So stands for intrinsic solubility of the pure component 
Depending on the type of curve formed, complexation is defined as either an A or a B 
type. ‘A’ type plots suggests formation of a 1:1 inclusion complex and are further classified as 
AL –linear increase in solubility as a function of CD concentration, AP –positively deviating 
isotherm and AN –negatively deviating isotherm. B-type plots are suggestive of less 
solubilization effect of CD and are often observed with β-CD’s [98]. 
 
Figure: 1- 5. Phase solubility plot of CD complexes 
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Complexation Efficiency (CE) 
 Cyclodextrins form inclusion as well as non-inclusion complexes with ligands. Also, 
CD’s tend to form aggregates, which becomes more prominent at high concentrations. Hence 
experimentally determined K values might not be an accurate representation of complexation 
phenomenon.  Determination of So values for poorly soluble drugs (<0.01mg/mL) from the shake 
flask method also can affect the K-values and result in an error. Complexation efficiency which 
is calculated from the ratio of complex to free cyclodextrin concentration is a more exact 
representation of the complexation process and can be calculated from the following equation 
(Eqn.1-3)[102]. Owing to their large molecular weight, CDs’ add significant weight to 
formulations and thus adding to final formulation weight. CE can be utilized to effectively 
calculate formulation bulk phase, which is significant in oral dosage forms.  
   
     
         
        Equation 1-3. 
Slope is calculated from the phase solubility plots mentioned earlier.  
1.3.3 Applications of CD complexation 
Cyclodextrins have a wide variety of applications due to their complex forming ability. In 
pharmaceutical industry they are frequently employed to increase bioavailability of poorly 
soluble drugs where dissolution is the rate limiting step. Cyclodextrins aid absorption of the drug 
in the lumen, by maintaining it in a solubilized state. Complexation, being a dynamic process, 
occurs simultaneously and involves association and dissociation of complexes. Precipitation can 
occur if this equilibrium goes beyond the solubility of drug, and addition of inhibitors such as 
PVP or HPC has been observed to be useful in such cases without affecting bioavailability [103]. 
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Sigurooardottir et al were able to utilize Maltosyl βCD (MbCD) and PVP to enhance transdermal 
permeability of hydrocortisone [104]. They observed that at higher concentrations a drop in flux 
was observed suggesting an upper limit to the concentration of MbCD that can be used for such 
applications. CD’s have also been utilized to stabilize substances from hydrolytic, oxidative, 
photolytic or enzymatic degradation. ɣ-CD’s have been used as a taste masking agent for bitter 
drugs obtained from natural sources [105, 106]. In food and cosmetic industry, they have been 
used as stabilizers and as taste masking agents and in pharmaceutical industry, they have been 
used as rate controlling agents, solubilizers, decrease tissue irritation, and as odor masking agents 
[107]. HPCD and RMβCD were able to enhance solubility and hydrolytic stability of Curcumin 
[108]. Various derivatives of β-Cd’s were utilized to enhance stability of an anti-parasitic agent 
to protect it from enzymatic as well as alkaline hydrolysis by forming complexes [109]. HPCD 
has been utilized to increase soubility in parenteral formulations [110]. Various CD’s have been 
investigated for their applicability in increasing the solubility of poorly water soluble drugs such 
as Miconazole [111], Itraconazole [112], Sertaconazole [113], Clotrimazole, Bifonazole [114] 
HPCD has been utilized to enhance release of a poorly soluble drug Carvediol from buccal 
adhesive patches [115]. CD’s have allowed for enhancement in nasal as well as transdermal 
absorption of certain drugs [116].
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CHAPTER II  
Objectives and Model Drugs 
2.1. Applicability and advantages of HME for solubility enhancement and as a processing 
tool for capsule and tablet formulations using Klucel™ EF and ELF polymers 
2.1.1. Objectives 
The utility of HME has been explored as a processing method to increase solubility of a 
poorly soluble model compound. HME was used to form amorphous solid dispersions of the 
drug in a hydrophilic matrix comprising Klucel polymers EF and ELF. The following 
objectives were accomplished in this work: 
 Pre-formulation studies were performed to evaluate thermal stability and 
miscibility of polymer and drug using TGA, DSC and Hot stage microscopy.   
 Formulation design and optimization of HME processes were performed to 
maximize yield for the manufacture of  pellets 
 Effect of drug loading and release modifying agents on in vitro release and release 
mechanisms involved were studied  
 In vitro release of direct compressed tablets manufactured from HME matrices 
were evaluated and compared to a marketed formulation 
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 The effect of storage conditions on formulations using Thermal, Chemical assay, 
XRD and release profiles of formulations stored at different storage conditions 
were studied 
Secondary objectives of this study include investigation of tabletting behavior of blends 
manufactured from HME matrices.  
o Tabletting profiles and conventional tablet characterization tests were conducted 
and evaluated 
 
2.1.2. Model Drug - Ketoprofen 
 
Figure: 2- 1. Chemical Structure of Ketoprofen 
 
Ketoprofen (KPR) is a white or off-white, odorless, non-hygroscopic, fine powder. It is 
freely soluble in ethanol, chloroform, acetone, ether and soluble in benzene and strong alkali, but 
practically insoluble in water at 20° C. The solubility in ethanol, DMSO, dimethyl formamide is 
at 20mg/ml.  The solubility of Ketoprofen in PBS pH 7.2 is 0.5 mg/ml. has a low solubility in pH 
1.2 buffer (0.06 μg/mL) and a high apparent permeability (> 1 × 10-6 cm/s). Ketoprofen is a 
BCS class II drug, hence dissolution is the rate limiting step for oral bioavailability. It is 
thermally stable, poorly soluble crystalline compound and was hence selected as a model drug 
for this study.   
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2.2. Formulation of controlled release film formulations utilizing polymers blends for water 
soluble drug via hot melt extrusion 
2.2.1. Objectives 
The applicability of HME technology for the manufacture of controlled release film 
formulation using a blend of Eudragit
®
 RSPO, Klucel
® EF and POLYOX™ N10 polymers were 
investigated. The advantages of intense mixing of an extruder to manufacture homogenous films 
from polymer blends that aid in tailored release profiles were evaluated. The research objectives 
can be summarized as below: 
 Thermal stability and miscibility evaluation of CLPM and other excipients  
 To compare Hot melt cast as a fast screening technique prior to HME  
 Optimization of HME process to extrude films with homogeneous drug and 
polymer distribution.  
 Characterization of films utilizing drug content analysis, in vitro release 
studies and chemical imaging techniques. 
 To evaluate in vitro release mechanisms involved, utilizing different kinetic 
models  
 To explore applicability of a selected film formulation for delivery through 
buccal mucosa for transmucosal delivery 
 Thermal and chemical stability evaluation of HME films at different storage 
conditions 
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2.2.2. Model Drug - Chlorpheniramine Maleate 
 
 
Figure: 2- 2. Chemical Structure of Chlorpheniramine Maleate 
 
 
 Chlorpheniramine maleate (CLPM) is an antihistamine that is commonly used in the 
treatment of various allergic conditions and to provide symptomatic relief from common cold. It 
is a low molecular weight amphiphilic drug, thermally stable, water soluble drug and was 
selected as a model compound. CLPM is absorbed very well, orally but, undergoes first pass 
metabolism thus reducing the amount of drug that is available for systemic circulation. A 
controlled release film formulation would ensure continuous release and also aid in avoiding first 
pass metabolism. 
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2.3. Clotrimazole-Cyclodextrin complex for treatment of vaginal candidiasis 
2.3.1. Objectives 
The objective of this research was to develop a gel formulation comprising a 
Clotrimazole cyclodextrin complex for treating vaginal Candidiasis. The research objectives can 
be summarized as follows. 
 To perform Phase solubility studies and HPLC analysis of complexes and 
understand the type of inclusion complex formed 
 Characterization of formed CT-CD complexes utilizing DSC, FTIR, NMR, SEM 
and PXRD studies 
 To formulate a mucoadhesive gel that can assist in administering CT-CD complex 
to the affected region 
 In-vitro release comparison studies of gel formulations manufactured from 
cyclodextrin CT complexes and, pure CT  
 Fungal assays to ascertain the efficacy of formed gels on Candida albicans, C. 
krusie and C. glabrata 
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2.3.2. Model Drug – Clotrimazole 
 
 
Figure: 2- 3. Chemical Structure of Clotrimazole 
 
 
 Clotrimazole (CT) is an Imidazole derivative having broad spectrum antifungal 
activity and has been used extensively in topical therapy for treating fungal infections. CT has 
been to found to be very effective in treating fungal infections, has very few side effects and is 
systemically less absorbed. CT is fairly lipophillic and has a water solubility of 0.49 mg/ml. The 
one significant drawback of a topical azole therapy is that it requires significant quantity of the 
drug and repeated application to maintain a therapeutic concentration. A CD complex can help in 
increasing solubility, thereby maintaining optimum concentration for effective management of 
candidiasis.
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CHAPTER III 
Applicability and Advantages of HME for Solubility Enhancement and as a Processing 
Tool for Capsule and Tablet Formulations Using Klucel™ EF and ELF Polymers 
3.1. ABSTRACT  
The objective of this research work was to evaluate Klucel™ Hydroxypropylcellulose 
(HPC) EF and ELF polymers for solubility enhancement of a poorly soluble drug. Ketoprofen 
(KPR), a BCS class II drug with poor aqueous solubility was utilized as a model compound. 
Preliminary thermal studies performed confirmed formation of a solid solution of KPR in HPC 
matrices and aided in establishing processing conditions for HME. Extrudates that were 
pelletized exhibited a carrier dependent release, with ELF exhibiting a faster release compared to 
the EF polymer. Tablets compressed from milled extrudates exhibited rapid dissolution, 
attributed to increased surface area from the milling operation. Addition of Mannitol (MNT) 
further enhanced the release by forming micro-pores thereby increasing the porosity of the 
extrudates. An optimized tablet formulation constituting KPR, MNT and ELF in a 1:1:1 ratio, 
exhibited 90% release in 15 min, similar to a commercial capsule formulation. HPC polymers are 
non-ionic, hydrophilic polymers that undergo polymer chain length dependent erosion and 
solubilization. The release obtained was carrier dependent and hence such a system can be 
utilized to address solubility issues with poorly soluble drugs.  
 
38 
 
3.2. Introduction  
 Pharmaceutical extrusion processes involves melting and blending of two or more 
components by a rotating screw in a heated barrel. The success of extrusion process is defined by 
the formation of a miscible, homogenous single-phase system, which remains stable for the 
duration of intended storage. HME is a thermally intense process which results in modification 
of physico-chemical properties of drug and excipients. The process of melting and mixing of 
drug and polymer/s at high temperatures leads to transformation, from which the original solid 
phase may never be completely regenerated [117]. These transformations include, but are not 
limited to, crystalline to amorphous transformations, solubilization of one component into 
another, or formation of immiscible micro crystals in the matrix [118].  
Solid dispersions (SD) are utilized in pharmaceutical industry for solubility enhancement 
applications. The processing steps involved in manufacturing of SD might induce a physico-
chemical transformation of the drug. Conversion to a high-energy amorphous form, being one of 
them, can impart enhancement in solubility and hence improve bioavailability [13, 119]. 
However, such high energy forms tend to recrystallize or precipitate out from their 
supersaturated solutions and hence stability assessment of such systems is of pivotal importance. 
Recrystallization and precipitation in these polymers can be controlled by the use of 
crystallization inhibitors [120] or by modifying the release to prevent supersaturation, but, at the 
same time maintaining a concentration that would result in bioavailability enhancement [15, 
121].  
Higher molecular weight grades of Klucel™ Hydroxypropylcellulose (HPC) polymers 
are commonly utilized as granulation binders [53], gelling agents or as release retarding agents 
[122]. HPC polymers are non-ionic, hydrophilic polymers that undergo dissolution by a swelling 
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and erosion driven mechanism. Prodduturi et al reported that the rate of solubilization of HPC is 
dependent upon polymer chain length, with longer chain molecules taking more time to swell 
and erode [51]. Lower molecular weight HPC’s with smaller chains undergo a faster erosion 
process, thus aid in immediate release and enhance solubility of poorly soluble drugs [14]. Being 
nonionic, pH independent release can be achieved from matrices manufactured from these 
polymers.  
Immediate as well as rapid release applications of Klucel polymers were evaluated for 
solubility enhancement. Lower molecular weight grades of HPC- EF and ELF, were utilized to 
increase the solubility of KPR by forming solid dispersion in a hot melt extruder. HME was used 
to intimately mix the components into a homogenous matrix. Ketoprofen (KPR) is a non-
steroidal anti-inflammatory drug commonly used in treatment of pain and inflammation 
associated with rheumatic disorders, ankylosing spondylitis, cramps associated with 
menstruation and osteoarthritis. Being a Class II drug, dissolution is the rate limiting step for 
absorption of orally administered KPR and hence, was used as a model compound [123]. Various 
techniques to increase solubilization of KPR have been explored including, formulation of solid 
lipid nanoparticles using waxes and lecithin[124], dispersing in pellets using macrogols[125], hot 
melt extrusion coupled with a cyclodextrin[126], self-emulsifying drug delivery systems[127] 
and  lyophilization[128]
,
[129]. Most of these techniques are multiple batch processes that might 
also involve the use of organic solvents. Further processing might thus be required to 
manufacture a final dosage form that can be administered to a patient. 
Preliminary screening studies were performed to evaluate HME feasibility utilizing DSC, 
Thermogravimetric analysis (TGA) and hot stage microscopy. The process was optimized and 
the extrudates were evaluated for in vitro release, crystallinity and surface morphology. 
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Extrudates were prepared into pellets, to be directly filled into capsules or milled to be 
compressed into tablets. The extrusion process converted crystalline KPR into an amorphous 
form, dispersing the same in a hydrophilic HPC matrix thus, resulting in an increased dissolution 
rate. We also have made an attempt to explain dissolution mechanisms that play a significant role 
in solubility enhancement. HME was utilized as a process of granulation with the added 
advantage of being a solubility enhancement technique. HME also imparted physical properties 
to extruded systems that contributed towards better tabletting properties. Amorphous forms tend 
to recrystallize on storage and Klucel™ polymers were able to maintain the drug in an 
amorphous form for a period of six months. 
 
3.3. Materials 
 Ketoprofen USP was purchased from Letco medical (1316 Commerce dr. NW, Decatur, 
AL, 35601); Klucel™ Hydroxypropylcellulose EF and ELF polymers (HPC) were obtained as 
gift samples from Ashland Aqualon functional ingredients (Wilmington, DW); Pearlitol
®
 
(Mannitol, MNT) was obtained as a gift sample from Roquette (1417 Exchange Street - PO Box 
6647, Keokuk. IA 52632). Ac-Di-Sol
®
 and Avicel
®
 200 were received from FMC biopolymers 
(1735 Market Street, Philadelphia PA 19103). Aerosil
®
 was received from Evonik Degussa 
Corporation (379 Interpace Parkway, Parsippany, NJ 07054). Magnesium Stearate was 
purchased from Mallinckrodt. The chemicals and reagents utilized were of analytical grade and 
obtained either from Fisher scientific (Fair Lawn, NJ) or Spectrum chemicals. 
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3.4. Methods 
3.4.1. Thermal Characterization Studies 
3.4.1.1. Thermogravimetric Analysis  
 PerkinElmer Pyris 1 Thermogravimetric analyzer (TGA) running Pyris manager software 
(PerkinElmer Life and analytical sciences, 719 Bridgeport Ave., Connecticut, USA) was utilized 
to perform thermo-gravimetric analysis of the samples. 3-4 mg. of the sample was weighed and 
heated from 25°C to 200°C at 10°C/min heating rate under an atmosphere of nitrogen and 
percent weight loss plotted against temperature.  
3.4.1.2. Differential Scanning Colorimetry   
 Polymer-drug miscibility studies were performed on two component mixtures of 
Klucel™ ELF and KPR at increasing concentrations ranging from 10% to 90%. A Perkin Elmer 
Hyper Differential scanning colorimeter (DSC) (Perkin Elmer life and analytical sciences, 710 
Bridgeport Ave., Connecticut, USA) was utilized. Thermograms were generated by analyzing 2-
3 mg. of the sample in an aluminum pan and heating it from 20˚C to 200˚C at a linear heating 
rate of 10˚C/min. Endothermic onset and peak temperature at melting were calculated from the 
software. Pyris™ manager software was used to control the instrument and analyze the data 
generated. Extruded systems were also evaluated similarly to evaluate crystallinity.  
Modulated Differential scanning colorimetric (mDSC) studies were performed on 
Thermal Analytics Q1000 mDSC instrument to detect glass transition temperature of amorphous 
systems. The samples were heated in hermetically sealed aluminum pans from -30° to 170°C 
with a 1°C/min modulation. Ramp rate was set to 3°C/min. The data was analyzed utilizing TA 
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Universal Analysis software and glass transition (Tg) temperature calculated by taking the 
midpoint of tangents drawn. Two step miscibility studies were performed on physical mixtures 
of H1 to H4 formulations. During first step, physical mixtures were heated to melt them and a 
second modulated DSC run was then utilized to evaluate phase transformations occurring. 
Extrudates were also evaluated for any recrystallization that might have occurred at the end of 
storage time points.  
3.4.1.3. Hot stage microscopy  
 Drug and excipient blends were evaluated using a Hot stage microscope and observed 
under polarized light for miscibility evaluation and changes in crystallinity. A small amount of 
sample was spread on a glass slide and inserted into a hot stage setup. Samples were heated at a 
constant heating rate of 10°C/min from 25°C to 200°C and visually observed. Images were taken 
continuously at different steps of transformation using a digital camera. 
3.4.1.4. Solubility parameters 
 Hansens 3d solubility parameters for KPR and the polymers were calculated from their 
chemical structures using Molecular Modeling Pro™ software (Fairfield, CA) . The solubility 
parameters (δt), account for Hydrogen bonding δh, polar interactions δp, and dispersive forces δd 
and can be used estimate miscibility between polymers and drug 
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3.4.2. HPLC Method  
  Samples were analyzed on a Waters HPLC and Empower software was used to analyze 
the data. The HPLC consisted of a Water 600 binary pump, Waters 2489 UV/detector and 
Waters 717plus autosampler (Waters Technologies Corporation, 34 Maple St, Miliford 
MA0157). A Waters Symmetry shield C18, 250X4.6mm, 5μm particle size reverse phase 
column was used as a stationary phase. Mobile phase comprising 55:45(%v/v), 
Acetonitrile:20mMol,pH 4 Phosphate buffer at a flow rate of 1ml/min was used [130]. The UV 
detector was set at 256nm wavelength. Extrudates and physical mixtures were analyzed by 
dissolving weighed samples in 20ml. of Methanol, filtered and injected at a 20μl injection 
volume. Content analysis for tablets was performed by disintegrating the tablets in water and 
extracting the drug in methanol prior to injection on an HPLC. All studies were performed as 
replicates of six. Samples from dissolution studies were filtered and injected at a 20μl injection 
volume similarly. 
3.4.3. Formulation – 
3.4.3.1 Formulation composition and HME processing 
HPC polymers, Klucel™ EF (EF) and Klucel™ ELF (ELF) were used at different drug 
concentration levels to evaluate their effect on solubility enhancement of KPR. Polymers and 
drug as per Table 3-1, were mixed in a V-cone blender (Maxiblend™, GlobePharma) at 25rpm 
for 10 minutes and samples analyzed for drug content and blend uniformity. The blended 
material were extruded on a 16mm. Prism Eurolab, ThermoFisher Scientific co rotating twin 
screw extruder utilizing a round shaped die to yield extrudate rods. The temperature of the barrel 
was maintained at 70°C to 140°C or 100°C to 140°C and screw speeds of 50 or 70 rpm. were 
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utilized. The extruded rods were collected on a Teflon coated conveyor belt and pelletized to 
yield 1mm. pellets utilizing a pelletizer (Type L-001-9482, Thermoscientific, Stone, UK). They 
were stored in Nitrogen filled plastic bags in a refrigerator until further evaluation. The pellets 
were evaluated for post extrusion drug content using an HPLC method. The pellets were packed 
in a size zero capsules to yield 50mg drug load or milled for tabletting. 
 
Table: 3- 1. Formulation Composition – Pellets 
 
Formulations Ketoprofen Klucel™ ELF Klucel™ EF Mannitol 
H1 
33 -- 66 -- 
H2 
33 -- 33 33 
H3 
33 66 -- -- 
H4 
33 33 -- 33 
H5 
25 75 -- -- 
H6 
25 37.5 -- 37.5 
H7 
45 55 -- -- 
H8 
45 27.5 -- 27.5 
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3.4.3.2. Tabletting 
 The extruded material was rendered brittle by freezing in a refrigerator and milled in a 
Fitzpatrick
®
 mill (The Fitzpatrick company, 832 Industrial drive, IL, USA), using hammers 
forward configuration for five minutes. The speed was maintained at 5000 rpm and sieve size 
corresponding to USP Sieve#18 used. Tablet blends were prepared as per table 3-2. 10 and 25 
mg. strength tablets were compressed on a Mendelco MTP1 tabletting machine using an 8 mm. 
biconcave punch, to a final tablet weight of 200 mg. A 50mg tablet was compressed using a 
11mm. punch with a composition similar to H4-25T, to be compared to a marketed formulation 
of similar strength. 10T and 25T represent tablet strengths 10mg, and 25mg respectively.  
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Table: 3- 2. Formulation Composition – Tablets 
 
Table: 3-2 H-10T formulations – adjusted by altering levels of MCC 
Excipients (% w/w) H1-25T H3-25T 
Ketoprofen 12.5 12.5 
Klucel™ ®  EF/ELF 25 (EF) 25 (ELF) 
Avicel
®
 200* 59.5 59.5 
Aerosil
®
 0.5 0.5 
AcDisol
®
 2 2 
Magnesium Stearate 0.5 0.5 
 
H2-25T H4-25T/50T 
Ketoprofen 12.5 12.5 
Klucel™ ®  EF/ ELF 12.5 (EF) 12.5 (ELF) 
Mannitol 12.5 12.5 
Avicel
®
 200 59.5 59.5 
Aerosil
®
 0.5 0.5 
AcDisol
®
 2 2 
Magnesium Stearate 0.5 0.5 
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3.4.4. Evaluation of Extruded system- Pellets and Tablets 
3.4.4.1. Moisture absorption studies 
 Extruded pellets were evaluated for percentage moisture uptake using saturated salt 
solutions. Pre-weighed plastic weight boats containing around 1 gm. of pellets (n=3) were stored 
at 35%, 50%, 65%, 75%, and 96%, RH chambers. Saturated salt solutions of Potassium Sulfate, 
Sodium Chloride, Magnesium Nitrate and Magnesium Chloride were utilized to maintain relative 
humidity’s of 90%, 75%, 60%, and 50%, respectively. At 0, 2, 4, 6, 7 and 14 days, weigh boats 
were taken out, weighed and put back in the shortest possible time. The percent                                                                                                                                                                                                                                                                                                                                                                                                                         
moisture uptake by the pellets was calculated from the percent weight gain as per the following 
equation: 
                         
               
         
              Equation 3.1 
3.4.4.2. Microscopy studies 
 Scanning Electron Microscope (SEM) was used to study surface morphology of extruded 
pellets. Samples exposed to dissolution media for ten minutes were also evaluated similarly, to 
study morphological changes post dissolution. Samples were sputter coated with gold using a 
Hummer
®
 6.2 sputtering system (Anatech LTD, Springfield, VA) in a high vacuum evaporator. 
A JEOL JSM-5600 scanning electron microscope operating at an accelerating voltage of 10kV 
was used for imaging. Samples were mounted on adhesive carbon pads placed on aluminum 
stubs prior to sputter coating.  
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3.4.4.3. In Vitro Release Studies 
 Extrudates equivalent to 50mg. KPR were filled into capsules and In-vitro release studies 
performed on a USP 31 Type I dissolution apparatus. Dissolution media constituting 900ml. of 
pH 6.8 phosphate buffer with 1% Tween
®
 80 added and maintained at 37°C was utilized. Paddle 
speed was set at 50 rpm. Samples were collected at every 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, and 5 
hours, filtered and analyzed using an HPLC. An equal amount of fresh dissolution media was 
added back to the dissolution vessel at each time point. Release profiles were plotted as 
percentage release to time.  
The dissolution profiles were compared utilizing model independent f2 similarity factor 
values, calculated as per the following equation. Dissolution profiles with values between 50-100 
are considered to be similar, with 100 being completely identical profiles [131]. 
 
          {[     ⁄  ∑    |     |
  
   ]
    
    }            Equation 3-2. 
 
3.4.4.4. Powder X-ray diffraction   
 Powder X-ray diffraction (XRD) studies were performed on a D-8 Advance X-ray 
diffractometer (Bruker AXS) equipped with a SolX detector and running DiffracPlus
®
 software. 
The generator voltage and current were set to 40KV and 30mA, respectively. The samples were 
scanned from 10° to 40°, 2Θ values with 0.05° ramp at 3 sec/step.  
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3.4.5. Stability testing 
 Samples were stored in closed glass bottles and evaluated for physical and chemical 
stability for a period of 6 months utilizing DSC, mDSC, XRD and chemical assay. Refrigerated, 
25°C/60%RH and 40°C/75%RH conditions were utilized. The studies were performed utilizing 
replicates of six. In-vitro release studies were performed on tablets stored at different stability 
conditions. The release profiles were compared based on calculated similarity factor values.  
 
  
50 
 
3.5. RESULTS AND DISCUSSION  
3.5.1. Thermal Characterization 
3.5.1.1. Thermo Gravimetric analysis 
 Thermal degradation was not observed with the excipients, however, KPR started to 
degrade at around 200°C (Figure 3-1). Extrusion conditions were maintained well below the 
degradation temperatures to maintain the stability of all the component systems. Klucel
TM
 
polymers are hygroscopic polymers and exhibited a 2-3% moisture uptake and hence were dried 
prior to extrusion.  
 
Figure: 3 - 1. TGA spectra of KPR and Polymers 
 
51 
 
3.5.1.2. Hot Stage Microscopy   
A hot stage microscope was utilized to replicate temperatures inside an extruder and 
observed under a polarized light microscope (PLM). Polarized light aids the differentiation of a 
crystalline form from a glassy/amorphous form [132, 133] and was hence utilized in this study. 
Crystalline KPR started to melt at around 97°C and converted to a molten form. HPC softened 
around 130°C and on melting completely, was found to be miscible with KPR (Figure 3-2.a). 
Similar transformations were observed in H2 formulations for HPC, KPR and MNT. However, 
MNT which melted at 170°C started to recrystallize back at 70°C (Figure 3-2.b).  The hot stage 
microscope confirmed the formation of a miscible amorphous system of KPR - EF mixtures.  
KPR-ELF systems exhibited similar results.  
a: HSM-PLM images of H1 formulation 
 
b: HSM-PLM images of H2 formulation 
Figure: 3-2. (a-b) HSM images of H1 &H2 Formulations 
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3.5.1.3. Miscibility Studies  
 At all the concentrations evaluated KPR and HPC were found to be miscible with each 
other. The onset temperature and endothermic melting peak of KPR were comparatively lower to 
that of pure KPR until a 60% drug loading. This suggested partial solubilization of KPR by HPC 
during the first heating step (Figure 3-4) [134]. KPR melting peak was not observed in second 
reheating step which confirmed formation of an amorphous KPR. H1-H4 physical mixtures as 
well as pure KPR were similarly evaluated on an mDSC. Pure KPR exhibited a Tg around 
0.85°C. HPC has been reported to have a Tg in between -25˚C to 0˚C which is dependent upon 
percent humidity [53]. Extruded formulations exhibited Tg in the range of 2˚C to 4°C suggesting 
this Tg to be that of a miscible single phase solid solution of KPR and HPC.  
Based on results obtained from thermal studies it was confirmed that KPR forms a solid solution 
with HPC polymers and were found to be miscible with each other. HME processing 
temperatures were set as per data obtained from DSC and hot stage studies.  
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Figure: 3 - 3. Polymer drug miscibility studies- DSC thermograms first heating step 
 
Figure: 3 - 4. Polymer drug miscibility studies- Onset and Peak Temperatures obtained 
from DSC thermograms 
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3.5.1.4. Solubility parameters 
Solubility parameters have been used to predict the miscibility of drugs and polymers in 
solid dispersions. Components with similar δt values suggest formation of a miscible system as 
the energy of mixing from intramolecular interactions is balanced with the energy from 
intermolecular interactions. Greenhalgh et al demonstrated that components with Δδt < 7Mpa
1/2
 
are likely miscible and  Δδt > 10Mpa
1/2
 to be immiscible [135]. Difference in δt values for drug 
and polymers, and between polymers was less than 7Mpa
1/2
 suggesting that they are miscible 
with each other. A δt value of 18.9 and 20.8 Mpa
1/2
 were obtained for KPR and HPC, 
respectively hence it can be assumed that the two components are miscible with each other as 
obtained Δδ values are less than 7 Mpa1/2. Thermal miscibility studies further support this.  
3.5.2. Hot melt Extrusion Process 
Klucel™ polymers, owing to their thermoplastic and thermostable nature have been 
utilized to form HME matrices earlier by Repka and co-workers [51, 122]. HPC polymers are 
semi crystalline polymers that soften over a wide range of temperatures from 100° to 140°C and 
have been extruded from 120°C to 170°C[136]
,
[137]. HME is a usually carried out at conditions 
that would either melt or soften the drug, or the excipients used. Additionally, plasticizers are 
employed to decrease viscosity, reduce the torque on the extruder and increase efficiency of the 
blending process. Earlier studies performed with HPC HF, a higher molecular weight grade of 
HPC, report the advantages of using plasticizers and also plasticizing effect of drugs [137]. KPR 
which melts at 97°C has been known to provide plasticization effect for the melt [130]. A similar 
effect was observed with our formulations and hence extrusion could be carried out at lower 
temperatures and higher screw speeds. Lower molecular weight polymers such as Klucel™ EF 
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and ELF, due to smaller chains, have comparatively lower viscosity and hence exert lesser 
torque. We were able to significantly decrease the extrusion temperature for ELF polymer and 
formulations with 45% drug loading to a temperature of 100-120°C. 
HME conditions such as barrel temperature and screw speed were optimized for 
maximum yield and were set according to observations made from thermal studies. A 
temperature setting of 100°C-140°C and 75rpm screw speed resulted in formulations with 
maximum yield. KPR on melting exhibits a tacky nature and cannot be extruded on its own 
without a matrix. Crowley et al tried to evaluate KPR-polyethylene oxide extrudates at a 30% 
level but were unable to extrude due its tacky nature [130]. HME performed on H7-H8 (45% 
drug load) exhibited slightly similar behavior as observed by Crowley et al, but could be 
extruded at a lower temperature of 110 to 120°C. Addition of mannitol significantly aided the 
extrusion and pelletizing process in these formulations. The extrusion conditions employed 
maintained MNT in a crystalline state (confirmed by DSC studies), provided a necessary 
backbone for the pelletization and milling operations.    
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Figure: 3 - 5. Effect of processing conditions on Post Extrusion drug content 
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3.5.3. Evaluation of Pellets 
3.5.3.1. Moisture Absorption Studies 
HPC are known hygroscopic polymers and hence moisture absorption studies were 
performed to evaluate the effect of moisture on HME extrudates. H1 & H3 pellets absorbed 
approximately 12% and 19% moisture, respectively, at 90% RH. H2 and H4 pellets absorbed 
approximately 6% and 9% moisture, respectively, at 90% RH (Figure 3-6-a,b). Pellets 
manufactured with ELF polymer showed comparatively higher moisture gain than EF pellets 
owing to increased hydrophilicity of ELF. H2 & H4 exhibited decreased moisture absorption 
relative to the H1 and H3 formulations and was attributed to lower hygroscopicity of MNT. 
Though such conditions are not routinely encountered, but these experiments suggest a possible 
weight gain in the extrudates and the need for proper packing material. Lower humidity 
conditions during manufacturing and moisture barrier packing during storage can effectively 
minimize moisture uptake. 
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a. Moisture uptake study - H1 and H2 formulations 
 
b. Moisture uptake study – H3 and H4 formulations 
Figure: 3 - 6. (a-b) Moisture uptake study – H1 to H4 formulations  
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3.5.3.2. Polarized light microscopy of Extrudates 
 Thin sections of extrudates were observed under polarized light at ten times 
magnification. H1 and H3, pellets exhibited a characteristic birefringence pattern observed in 
polymers on extrusion. Phase separation and crystalline character were not observed confirming 
formation of a single phase, miscible, amorphous system. H2 and H4 formulations, exhibited a 
crystalline characteristic owing to presence of Mannitol (Figure 3-7). 
 
 
Figure: 3 - 7. PLM images of extruded pellets – H1, H2, H3, and H4 
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3.5.3.3. Scanning Electron Microscope 
 Formulations manufacturing KPR and HPC exhibited a smooth surface suggesting a 
completely miscible single phase system. Formulations comprising MNT exhibited a similar 
smooth texture which was dispersed with crystalline mannitol. Images 3.6.a-e represents H5, H3, 
H4, H7 and H8, formulations respectively. Extrudates representing higher drug loading 
formulations, H7 and H8, exhibited smooth surface which were interspersed with fissures. These 
fissures or cracks might have been formed during the cooling phase of extrusion process. HPC is 
a long chain, viscoelastic polymer that can expand or contract owing to flexibility of its polymer 
chains. A small molecule such as KPR lacks such viscoelastic characteristics and apparently 
might have resulted in unequal contraction during cooling, resulting in development of cracks in 
the matrix. It was also observed that on extrusion these formulations exhibited decreased dye 
swelling owing to decreased polymer levels.  
3.5.3.4. Differential Scanning Calorimetry studies  
DSC and mDSC studies performed on extruded pellets confirmed formation of a single 
phase solid solution of KPR and EF/ELF. A single Tg and a crystalline peak for MNT were 
observed in the thermograms confirmed the physical state of component systems. 
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Figure: 3 - 8. a-e SEM images of pellets manufactured using Klucel™ ELF polymer 
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3.5.4. In Vitro Release Studies 
3.5.4.1. In Vitro release studies - Pellets 
 Formulations manufactured utilizing ELF polymer exhibited faster release in comparison 
to EF pellets. A release of 52.7±0.6% and 74.5±1.6% in one hour for H1 and H3 formulations, 
respectively, was observed. Formulations with mannitol, H2 and H4, released 85.8±3.6% and 
88.5±1.5%, drug respectively. The extruded formulations, H2 to H8, had a comparatively faster 
release than an equivalent un-extruded KPR, (Figure 3.9). H1 formulation comprising EF 
polymer did not show a significant improvement over physical mixture blends (f2 value of 62). 
However, addition of mannitol in H2 as well as H4 resulted in an improvement in release. 
 
Figure: 3 - 9. In Vitro release of EF and ELF pellets 
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HME involves mixing of molten drug and polymers resulting in formation of a solid 
solution or dispersion of drug in a polymer matrix. Such dispersions, due to their inherent 
advantages, have been utilized to increase solubility of poorly soluble drugs [119]. In our work 
Klucel™ polymers were able to disperse amorphous KPR at a molecular level in a hydrophilic 
matrix. HPC enhances the dissolution process by increasing the wettability, surface area and also 
aids in stabilization of amorphous KPR [118]. Hydroxylpropylcellulose polymers undergo 
dissolution via a swelling and erosion driven mechanism which is dependent upon chain length 
[50]. Longer chain polymers require a longer time to erode and hence result in slower release. 
Klucel™ ELF and EF polymers have a comparatively lower molecular weight and undergo faster 
erosion, resulting in immediate release of KPR. Amongst the polymers used, ELF matrices 
exhibited a faster release owing to smaller polymer chain length and molecular weight.  
Yuasa et al and Prodduturi et al reported similar polymer chain length dependent release of 
poorly soluble drug from different grades of HPC [37, 50, 138]. The factors – increased surface 
area, amorphous form and a hydrophilic matrix contribute towards an increase in dissolution 
rate. In addition, Mannitol due to its high solubility, creates micro-pores in the matrix by 
solubilizing at faster rate and enhances release significantly [139, 140]. During HME process 
molten polymer tends to densify on being pushed through a die - resulting in decreased porosity 
[41]. MNT might have also compensated for this decrease in porosity, as it is non-compressible 
agent compared to rest of components.  
Hydrophilic polymer based solid dispersions has gained interest over the last decade due 
to a growth in the number of poorly soluble compounds reaching development phase. However, 
this technology comes with a caveat that formulations performing well in vitro, may fail in vivo 
testing. Carrier mediated or drug related phase conversion or precipitation, occurring in these 
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formulations has been reported to be the reason for such unexpected release. SDs rely on 
hydrophilic polymers to increase wettability and an amorphous form of the drug to increase drug 
solubility in the media. These polymers tend to solubilize at a faster rate leaving behind a super 
saturated drug which might result in solution mediated phase conversion [16]. Sheen et al 
observed that solid dispersion using melt technology did not result in an increased bioavailability 
and suggested that this could be due to precipitation of the poorly soluble drug in gastric media 
[141]. Dinunzio et al observed that formulations which exhibited a slower release over a 
prolonged period of time resulted in better bioavailability by preventing super saturation and 
recrystallization of Itraconazole [121]. Similarly, Law et al concluded that a slower release 
would benefit bioavailability as the precipitated crystalline form would require more media to 
undergo dissolution [15]. Thus a slower release, still in the domain of immediate release, might 
actually contribute towards increased bioavailability and better stability for SD. Klucel polymers 
with a wide range of molecular weights and non-ionic character can be rightly selected to tailor 
such release that is carrier dependent and also prevent precipitation or recrystallization.  
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3.5.4.2. Effect of Drug loading 
 The dissolution profiles of pellets extruded at different drug loads of 25%, 33% and 45%, 
were compared (Figure 3-10). Formulations H7 and H9 with 25% and 45% KPR, respectively, 
had similar release profiles as H3 (33% KPR) formulation (Table: 3-3). It was observed that an 
increase in KPR concentration decreased its release in one hour from 74.5±1.6% to 65.7±3.5%, 
for H3 and H9 formulations, respectively. A similar trend was observed with Mannitol and ELF 
formulations, H4, H6 and H8. H4 formulation with an equal distribution of KPR, ELF and MNT 
(1:1:1) released the drug in the least amount of time. In all the formulations studied, pellets 
manufactured utilizing ELF exhibited a faster release but at higher drug loading of 45%, no 
significant improvement in the release of KPR was observed. 
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Figure: 3 - 10. In vitro release of KPR pellets at different drug loading 
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Table: 3- 3. Effect of drug loading on in vitro release, f2 values 
 
Excipients Formulations 
ELF H3 H5 H7 
% Release in 1 h 74.5±1.6 75.50±1.1 65.7±3.5 
 H3-H5 H3-H5 H5-H7 
f2 56 55 44 
ELF+MNT H4 H6 H8 
% Release in 1 h 88.5±1.5 68.3±4.0 75.1±3.0 
 H4-H8 H4-H6 H4-H8 
f2 43 39 66 
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As per Higuchi’s matrix model, release from a matrix occurs by dissolution and diffusion 
of one component through the other through formation of channels in the matrix [142]. Due to 
difference in solubility, component with higher solubility solubulizes at a faster rate leaving 
behind component with comparatively lesser solubility [143]. Tortuosity defines the 
irregularities in the channels created during dissolution and has a significant effect on the 
diffusivity of a drug. At higher drug loading (45%), less soluble KPR forms infinite or 
continuous clusters thereby increasing tortuosity, preventing surface penetration and thereby 
dissolution [144]. In formulations such as H4, HPC and MNT undergo rapid solubilization 
forming channels resulting in decreased tortuosity and increasing diffusivity of the dissolution 
media. A similar decrease in release has been observed in extruded matrices by Crowley et al 
and Zhang et al which was attributed to decreased penetration of dissolution media [74, 145].  
Amorphous forms utilized in SDs can revert back to their crystalline forms or may 
precipitate out on exposure to dissolution media. An increase in drug loading resulted in a 
decreased release and a drop in bioavailability for Ritonavir (RTR) based solid dispersions. This 
drop in release was attributed to a localized phase conversion of amorphous RTR to a crystalline 
form [15]. These transformations in the solid state can be minimized by the use of appropriate 
polymers and recrystallization inhibitors. However, solution mediated drug transformations 
require specific techniques to maintain super saturation. KPR exhibited miscibility of 
approximately 60% in DSC studies without undergoing any recrystallization on cooling. We 
assume that there might be a localized recrystallization of KPR on contact with the dissolution 
media, thus affecting release. This phase conversion, if any, can be considered to be solution 
mediated and not carrier mediated. 
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3.5.4.3. SEM evaluation of pellets at different drug loading 
SEM was utilized to evaluate morphological changes occurring in pellets exposed to 
disso media. SEM images of H5 (25% KPR) pellets exhibited a significant change in 
morphology on dissolution which can be attributed to soluble ELF and MNT (Fig. 3B-I). It was 
observed that H5 (Fig 3B-I), on dissolution, exhibited significant changes in morphology. The 
dented appearance was formed due to rapid solubilization of hydrophilic excipients by an inward 
moving solvent front. The soluble polymers formed channels allowing media to enter the matrix.    
On comparison of SEM images of pellets, post dissolution samples exhibited a smoother surface 
in contrast to an uneven texture formed during extrusion, supports surface dissolution of HPC 
(Figure. 3.11, I-IV).  
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Figure: 3 - 11 (I-IV) SEM images of pellets manufacture using Klucel™ ELF polymer – 
Post exposure to dissolution media 
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3.5.4.4. In Vitro release studies – Tablets 
 Extrudates were milled and compressed into tablets with the addition of MCC as a direct 
compression vehicle and Ac-Di-Sol
®
 as a disintegrant. Tablets exhibited faster release in 
comparison to pellets and followed a similar rank order (Figure 3-12). HME exerts compressive 
forces on molten material that results in densification, decreased porosity and surface area. These 
problems were addressed by milling the material and using a super disintegrant to disperse the 
same. Tablets manufactured from H4 matrices exhibited rapid release in comparison to rest of 
the formulations (Table 3-4). H3-25T showed a slower release when compared to other tablet 
formulations. ELF polymer, being more plastic forms a denser and less porous compact on being 
compressed thus slowing the release [53]. This increased compactibility also resulted in 
increased tensile strength and has been further detailed in the tablet characterization section. 
Table: 3- 4. % In vitro release from tablets at 25mg strength in 30 min. 
 
Formulation % Release in 30 min 
H1-25T 77.2±0.5 
H2-25T 76.3±2.6 
H3-25T 58.6±3.2 
H4-25T 88.7±6.3 
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Figure: 3 - 12. In Vitro Release profiles of tablets at 25mg. strength 
 
 H4 pellets comprising Klucel ELF polymer were utilized to manufacture tablets to be 
compared to a marketed KPR capsule. Tablets were compressed to a 50mg strength utilizing 
11mm. round biconcave punch to a tablet weight of 400mg. The percentage drug release in 
fifteen minutes was 92.8±4.4% and 87.0±1.3%, respectively, for H4-50T and marketed 
formulation. We were able to successfully utilize extrusion process to manufacture immediate 
release tablet formulations of KPR utilizing Klucel polymers. The milled matrices utilized in 
tablet formulations exhibited faster release in comparison to pellets due to particle size reduction 
of extrudates. The dissolution profiles are presented in the Figure 3-13. 
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Figure: 3 - 13. In Vitro Release comparison to a marketed capsule formulation 
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3.6. Stability Testing –Pellets and Tablets 
 Physico-chemical analysis was performed on pellets that were stored at room and 
accelerated stability conditions for a period of six months. HME process converts crystalline 
drug to an amorphous form which tends to recrystallize on storage. Increased temperatures and 
presence of moisture further enhances this phase conversion. mDSC and DSC studies were 
utilized to analyze the physical state of the drug and excipients post storage. mDSC confirmed 
the presence of an amorphous form of the drug based on the glass transition temperatures (Tg) 
and lack of crystalline melting peaks (Figure 3-14). All the extruded pellets were found to be 
chemically stable for a period of six months at the storage conditions tested. The percent drug 
remaining at the end of last time point was more than 95% after six months of storage at 
40°C/75% RH.   
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Figure: 3 - 14. mDSC thermograms of Pellets - 6 months stability 
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Figure: 3 - 15. DSC thermograms Pellets -6 month’s stability 
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Tablets  
 The crystallinity was evaluated utilizing XRD studies. KPR remained in an amorphous 
form in XRD spectra. Crystalline peaks of KPR at 2θvalues corresponding to 14.2, 18.4, 22.9 
[126, 130] were absent in tablets mixtures at the end of storage time points (Figure 3-12). Tablets 
remained chemically stable in all the formulations for a period of six months. Tablets stored at 
40°C/75% RH showed comparatively slower release compared to initial release profiles. H4-50T 
Tablets stored at 25°C/60% RH had similar profiles to their initial release profiles (Figure 3-10). 
 
 
 
Figure: 3 - 16. XRD images of H4-25T tablets: 6 months storage time point 
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CONCLUSION 
Multi-particulate dosage forms such as pellets, with a proper dispensing device, can be 
utilized to answer some of the unmet needs in the pharmaceutical industry [146]. Conventional 
pelletization techniques utilize solvents and are typically batch processes. HME is a non-solvent 
continuous process and hence is considered a faster technique [147] for the manufacture of 
multi-particulate delivery systems.  
We were able to successfully utilize Klucel™ Hydroxypropylcellulose polymers as HME 
matrix formers, granulation and solubility enhancing agents. Feasibility evaluation of HPC was 
performed and its advantages in forming and maintaining solid solutions detailed. Hot melt 
extrusion technology is being extensively explored to increase solubility of poorly soluble drugs. 
However factors such as high temperatures, drug-excipient stability, phase separation or 
conversion are essential for long term stability. We also explored the advantages of HME 
process as a technique that can be used as a technique with added an added benefit of increased 
tabletability of the matrices. The formulations were chemically and physically stable for a period 
of six months under accelerated stability conditions. The release profiles obtained were similar to 
the marketed formulation. Klucel™ polymers have been typically used as binders in granulation 
and as control release polymers. We were able to explore the possibility of utilizing these 
polymers as immediate release excipients and also as stability imparting polymers. A 
formulation approach to form multi particulate delivery systems is outlined and with proper 
delivery device, could be adopted for ‘dose as per need’ dosage forms. HME is a versatile tool 
which can be modified for wider applications and a suitable polymer expands this applicability 
significantly. 
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CHAPTER - IV 
Characterization of Tabletting Behavior of Blends Manufactured From Hot Melt Extruded 
Matrices 
Abstract 
 Hot melt extrusion technology was utilized to form amorphous solid dispersions of a 
poorly soluble drug, Ketoprofen and Klucel™ EF/ELF polymers. The extrusion process allowed 
for intimate mixing of components, which on cooling formed an indiscernible homogenous 
matrix. In addition to increase solubility, matrices exhibited unique properties that affected 
tabletting behavior of the blends. Compactibility, Tabletability and Compressibility profiles were 
generated and compared for HME matrices as well as physical mixtures. Conventional tablet 
characterization techniques were also performed simultaneously on tablets manufactured on an 
automated tabletting machine. A Texture Analyzer was utilized to measure the work involved 
during tabletting breaking and extent of tablet deformation before breaking. Tablets 
manufactured from extruded matrices were found to be more plastic and underwent a significant 
change in morphology prior to breaking.  
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4.1. Introduction 
Granulation is a standard unit operation commonly employed to increase particle size, 
maintain content uniformity, improve tabletting properties and address problems such as poor 
flow [148]. Traditional granulation techniques include blending, activation of binders and drying 
steps to remove solvents, prior to milling to form granules. However, limitations with these 
methods include– limited drug loading, solvents and sharp granulation end points. HME has 
been explored as a granulation alternative due to various reasons. It is a continuous process with 
no or very less solvent requirement, the agitation brings about intimate mixing of components 
and if required, heat can be applied to further speed up the drying process. HME was used to 
manufacture high drug loaded formulations, which were otherwise not feasible through 
conventional granulation techniques [38, 149]. Also, formulations manufactured from HME 
exhibited better tabletting properties in comparison to tablets obtained from roller compaction or 
wet granulation. Utilization of twin screw extruders as a continuous granulation tool has been 
explored by Keleb et al. Water was used to activate the binders and the extrudates cut into tablets 
[150]. HME was utilized to enhance tabletting properties of Isomalt, which was used as a filler 
excipient [70].  
In this work, HME was utilized to manufacture solid dispersions of KPR to enhance its 
solubility. The metering sections and die exert considerable amount of pressure on material 
which results in compaction and hence a decrease in porosity. Milling operations aid in 
disintegration of extrudates and increase surface area brought about by particle size reduction. 
Thus, tabletting allows for dosage forms that can easily disintegrate and disperse the extrudate 
material, aiding in faster release. As mentioned earlier, HME imparts physico mechanical 
properties to extrudates that results in a significant improvement in tabletting properties. Lower 
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molecular weight grades of HPC have been utilized at 1-2% level as granulating agents and at 
30-40% level as release modifiers due to their matrix forming ability [53]. Also, HPCs have been 
found to prevent capping tendency in tablets manufactured on high speed tabletting machines 
[151]. Smaller chain polymers have less of an elastic relaxation in comparison to longer chain 
polymers and aid in reducing capping. 
Compactibility profiles of extrudates and un-extruded blends were generated and 
compared to evaluate effect of HME on tabletting. Tablets were also evaluated using 
conventional testing and using a texture analyzer to understand the dynamics involved during 
tablet breaking. These mechanistic studies aid in better understanding of the effects of polymers 
and processing conditions on tabletting properties.  
4.2. Materials and Methods 
The following chemicals were used as obtained: Microcrystalline cellulose (MCC; 
Avicel
®
 PH101) from FMC biopolymers (Newark, DE), Dicalcium phosphate (DCP; DiTab
®
) 
from Stauffer Chemicals (Tampa, FL), Pregelatinized starch (Lycatab
®
) and Mannitol 
(Pearlitol
®
) from Roquette America Inc., (Keokuk, IA), Lactose monohydrate (lactose; 
Pharmatose
®
) from DMV-Fonterra excipients (Germany), and Magnesium stearate from Alfa 
Aesar (Ward Hill, MA); Hydrochloric acid (HCl), Sodium hydroxide (NaOH), 3% v/v Hydrogen 
peroxide (H2O2) and Orthophosphoric acid were obtained from Fisher Scientific (Fair Lawn, 
NJ).  HPLC grade water was freshly prepared in the laboratory by Nanopure systems (Barnstead, 
Dubuque, IA). All solvents utilized in the study were of analytical grade and obtained from 
Fisher Scientific (Fair Lawn, NJ). 
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4.2.1. Excipient compatibility studies  
 Tablet excipient compatibility was performed by preparing 1:1 binary mixtures of 
commonly used tabletting excipients and drug, evaluating them for a period of 2 weeks. The 
blends were exposed to 60°C heat in open bottles and analyzed utilizing a DSC at initial, 7 and 
14 day time points. DSC method, mentioned earlier, was used to evaluate the stability of the 
samples by comparing thermograms at different time points. The following excipients were 
utilized for this study:  Xylitol, Isomalt, Mannitol, Primojel, Crospovidone, Emcompress, 
Avicel-102, Sugartab, Magnesium Stearate, Sodium Stearyl Fumarate, Glycolys and Ac-Di-Sol
®
. 
4.2.2. Tablet characterization  
 Standard characterization tests were performed on tablets manufactured from extruded 
material. The thickness and diameter of the tablets was measured using a micrometer. 
Disintegration testing was performed on a Dr. Schleuniger Pharmatron USP (Schleuniger 
Pharmatron Inc., 1 Sundial Ave., Manchester, NH 03103) disintegration apparatus. Friability 
testing was performed in a friabilator (Roche friabilator). A Varian VK200 (Agilent 
Technologies, 13000 Weston Parkway, Cary, NC, 27522) hardness tester was utilized to test the 
hardness of tablets. Each tablet was placed diametrically between the anvils of the instrument 
and the force required to break the tablets measured. Six replicates were tested and the values 
averaged out. Tensile strength was calculated from hardness values utilizing the following 
equation. F is the force measured at tablet failure or breaking, d and h are the diameter and 
thickness of the tablet, respectively.  
  
  
   
                Equation 4-1. 
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4.2.3. Compaction profiles 
 Compaction profiles were generated for extruded and un-extruded KPR formulations as 
per their definitions[152]. A hydraulic Carver press (Fred Carver, Menomonee, WI) was used to 
compress  tablets at different compaction pressures ranging from 50MPa to 500MPa using an 8 
mm. punch. Tablets were tested for hardness and, tensile strength calculated. True density 
measurements of the tabletting blends were performed using a Micromeritics Helium 
pycnometer (AccuPyc II 1340, Norcross, GA 30093). Porosity measurements were made by 
calculating the true density of the tablets and utilizing it to calculate the percent solid fraction (S) 
in the tablet. The percent porosity (Ɛ) was calculated using the following equation: 
                              Equation 4-2 
 Tabletability is represented by a plot of tensile strength versus compaction pressure, 
Compactibility by a plot of tensile strength versus porosity and Compressibility by a plot of 
porosity versus compaction pressure [153].  
4.2.4. Texture analyzer 
 TA-XT Plus Texture Analyzer (Texture Technologies Corp., Scarsdale, NY) was used to 
calculate the hardness, work of failure and percent change in diameter at tablet failure. A TA-8 
ball probe was used to exert diametrical force on a vertically placed tablet. The test probe 
travelled at 2 mm sec
-1
 until the tablet surface was detected at 0.05 N, after which the probe 
travelled to a 3mm distance. A 10kg load cell was used to register the force exerted till the point 
of tablet breaking. 
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Figure: 4 - 1. Texture Analyzer plot 
 
  
85 
 
4.3. RESULT AND DISCUSSION 
4.3.1. Tablet – Excipient Compatibility studies 
Excipient stability studies are important to assess long term stability of a formulation. 
Though the concentrations used and the temperature the studies are performed do not replicate 
the actual storage conditions, their aim is to maximize any interactions that might occur that 
would suggest drug degradation. No interactions were observed with the excipients used (Figure 
4-1). KPR peak exhibited a slight deviation in KPR:Avicel and KPR:Isomalt mixtures. Isomalt 
melts around 100°C and loss of moisture from Avicel might have resulted in such deviations and 
do not suggest incompatibilities. Thermograms generated for KPR with Magnesium Stearate 
showed some interactions as the melting peak of KPR had shifted. Stearates have been found to 
be incompatible with KPR and also other drugs [154]. At the concentrations used and presence 
of KPR in extrudates such incompatibilities might not affect the stability of the drug.     
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Figure: 4 - 2. Excipient compatibility studies - DSC thermograms, Post storage of 14 days 
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4.3.2. Compactibility Profiles 
 Compactibility, Tabletability and Compressibility of HME tablets and tablets 
manufactured using un-extruded blends were studied. HME results in a physical transformation 
of drug and excipients which influences tabletting behavior. Compressibility, Compactibility and 
Tabletability profiles as described by Tye et al were utilized to understand the effect of melt 
extrusion on tabletting [155].  
Compressibility is defined as an ability of material to undergo a reduction in volume as a 
result of an applied pressure. Compressibility profiles did not exhibit any difference among 
extruded formulations (Figure 4-2). However, extruded blends were found to be more 
compressible compared to un-extruded formulations. The increased ability to form compacts can 
be attributed to increased plasticity of the extruded material [156].  
 
Figure: 4 - 3. Compressibility profiles of extruded matrices 
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Compactibility profiles can be used as a measure or tendency of a material to be 
compacted and is plotted as change in tensile strength to percentage porosity (Figures 4-3). It can 
also be defined as how good a compact can be prepared on tabletting of the blend. Un-extruded 
T1, T2 formed better compacts at lower compaction pressures but exhibited capping at higher 
compaction pressures. Un-extruded formulations manufactured utilizing ELF polymer did not 
exhibit any capping for (T3 and T4) even at higher compaction pressures. Similar observations 
were made by Martino et al [151]. H3-25T tablets were plastic in nature and as they did not 
break during hardness testing, profiles could not be generated. EF and ELF retained their 
compaction properties post-extrusion. H3-25T tablet formulations had a plastic nature and did 
not break under the hardness testing and hence tensile strength could not be measured. Of all the 
tablets compared H4-25T was found to be more compactable than the remaining formulations 
owing to the presence of ELF which is a lower molecular weight grade of HPC. Addition of 
Mannitol might have decreased the compactibility of H4-25T in comparison to other 
formulations. 
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Figure: 4 - 4. Compactibility profiles of extruded matrices 
 
With a decrease in molecular weight of HPC, compactibility and plasticity increase with 
a consequential decrease in elasticity [53]. Smaller chain length ELF polymer hence exhibits less 
elastic recovery, higher plasticity and undergoes a greater deformation forming better compacts 
on being compressed. Also, HME converts the drug and HPC to an amorphous form leading to a 
subsequent increase in surface area for bonding between the tabletting excipients [156]. This 
transformation could be a reason for increased tabletting properties of extruded systems. Also, 
the smaller chains in ELF might have contributed towards a lesser elastic recovery and hence no 
capping was observed in tablets at higher compaction pressures for un-extruded tablets T3-25T –
T4-25T. Un-extruded formulations were utilized as controls and behaved similarly or slightly 
better than extruded formulations in these tests. 
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Tabletability profiles are plotted as tensile strength vs. compaction pressure are useful 
tools to establish tabletting behavior of formulation blends. The extruded systems had similar 
tabletting properties as un-extruded blends. The extruded formulations did not exhibit an in 
tensile strength after a certain point. Among all the formulations tested, H4-25T exhibited better 
compactibility and tabletability (Figure 4-4). 
 
Figure: 4 - 5. Tabletability profiles of extruded matrices 
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4.3.3. Tablet characterization tests 
Tablets manufacture on a tabletting machine passed all the standard tests such as weight 
variation, friability and disintegration testing. Hardness testing was performed on tablets 
compressed at same compaction pressure. H1-25T, H2-25T, H3-25T and H4-25T exhibited 
hardness values of 99.8±7.7, 79.9±3.0, 108.6±2.6 and 88.5±5.5 Newton, respectively, (Figure 4-
4). Addition of mannitol resulted in a decrease in hardness values. Mannitol, a crystalline 
excipient, on compression undergoes plastic deformation whereas HPC has a viscoelastic 
character that aids in holding the matrix together. HPC is considered a good binder in 
conventional tableting operations and is used extensively. A similar behavior was observed in 
HME extruded matrices, with Klucel™ ELF having better performance than EF.    
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Figure: 4 - 6. Tablet Hardness evaluation – Extruded vs. Un-Extruded 
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4.3.3. Hardness evaluation utilizing Texture analyzer 
 The classical hardness testing registers force required for a tablet to fail or break) under 
an applied diametrical force, between two anvils. However, the test fails to register the dynamics 
involved prior to point of failure and hence, a texture analyzer was utilized to analyze the same. 
Tablets were compressed at a constant compression force and evaluated utilizing work of failure 
(Wf) and percent change in diameter (Cd) at tablet failure. The area of the plot - force to distance 
travelled, can be utilized to calculate work done during diametrical breaking of a tablet and is 
represented as work of failure. The peak of the plot denotes the force at breakage and can be 
simultaneously used to calculate the distance travelled by the probe from the point of contact to 
the distance causing a break. During testing a probe exerts a diametrical force at a constant speed 
onto the tablet and load cell registers the change in force to distance displaced by the probe. 
Tablets manufactured from extruded matrices were more resistant to breaking in comparison to 
un-extruded tablets. The extent of deformation, as measured by the percentage change in 
diameter and work of failure was higher for extruded tablets (Figure 4-5). These observations 
correlated with the data generated from compaction profiles. 
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Figure: 4 - 7. % Change in Diameter on compression 
 
Figure: 4 - 8. Work of failure at tablet failure 
95 
 
CONCLUSION 
 Hot melt extrusion is a versatile technology that can be adapted easily to manufacture a 
variety of dosage forms with slight modification. HME using Klucel polymers imparted 
interesting characteristics to extrudates that aided in improvement in release, as well as tabletting 
properties. Klucel™ ELF polymers formed better compacts and were also able to prevent a 
capping tendency in un-extruded tablet formulations. Extruded matrices imparted a plastic 
behavior to the tablets and were found to better resist deformation, or breaking. These findings 
represent a significant role in improving handling, packaging and coating operations after 
tabletting. 
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CHAPTER V  
Custom – Controlled Release Formulations Utilizing Polymer Blends And Hot Melt 
Extrusion For A Water Soluble Drug 
5.1. Abstract 
  The aim of this project was to investigate the effect of sustained release polymer blends 
on the release of a highly water soluble model drug, Chlorpheniramine maleate (CLPM). 
Eudragit
®
 RSPO and Klucel™ EF were utilized to control the release of CLPM from 
POLYOX™ N10 matrices. Thermogravimetric analysis, Differential scanning calorimetry, and 
solubility parameters were utilized to evaluate stability and miscibility of component systems for 
hot melt extrusion. Hot melt casting method was utilized as a preliminary screening method to 
evaluate the effect of polymer blends on release. HME films manufactured were evaluated using 
near infra-red chemical imaging to study the effect of particle size on distribution of the drug and 
polymers in the matrix. Polymer blends of RSPO and HPC were found to be better in attaining 
sustained release than when used alone. C7 formulations comprising 20% HPC and 25%RSPO 
released 76±5% drug in two hours whereas HPC and RSPO alone released the same amount of 
drug in 30 min and 1 hr respectively. Increase in concentration of HPC significantly delayed the 
T80% release from 6 hr to 29 hr at 30% and 55% concentrations. Release profiles were fit using 
least squares regression to evaluate the effect of polymer concentration on release. A 90% 
regression was obtained suggesting the applicability of polymer blends in attaining a tailored 
release.  
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5.2. Introduction 
Polymeric matrices have often been used to alter drug release, so as to bring about 
immediate or prolonged therapeutic effect. Many methods have been mentioned in the literature 
that bring about modified release such as, using polymers in tablets that form a matrix in situ 
[157] or use of polymeric coating methods [158]. Hydrophilic as well as hydrophobic polymers 
have been extensively used to control drug release from pharmaceutical dosage forms. These are 
either water soluble of cellulosic esters or insoluble acrylic polymers. Based on the release 
intended, polymers can be selected to render a zero order, pulsatile, sigmoidal release, or targeted 
release profiles [159]. 
 Cellulosic ether derivatives such as Hydroxypropyl Methyl cellulose (HPMC), 
Hydroxypropyl Cellulose (HPC), Hydroxyethyl cellulose (HEC), and Ethyl Cellulose (EC) are 
frequently utilized for modified release applications. These are the most preferred polymers for 
controlled release applications due to their swelling as well as compressible characteristic that 
aids tabletting. HPC polymers are available in different grades with higher molecular weight 
grades commonly utilized as gelling agents or as release retarding agents [122]. HPC and HEC 
polymers, owing to their stability and release characteristics have been utilized in HME 
processes to manufacture modified release formulations [36, 37, 47, 48]. Eudragit RSPO 
polymers are copolymers of ethyl acrylate, methyl methacrylate and methacrylic acid ester with 
quaternary ammonium groups that render these polymers permeable, which otherwise, are water 
insoluble [86]. Eudragit
®
 RSPO and RLPO have been utilized to control release of indomethacin 
[43] and Chlorpheniramine maleate [160] from solid solutions manufactured via HME. Also, 
HME processing was better able to retard release in comparison to traditional granulation or 
direct compression methods.  
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Manufacture of such polymeric systems typically employs coating processes, the 
functionality of which depends upon thickness and uniformity of the polymer film. End point 
determination of coating processes is usually assessed by weight gain or by a time consuming 
disintegration test [161]. Film coating performed on a fluid bed processor or pan coating may 
lead to non-uniform coating leading to failure of such dosage forms due to formation of channels 
[158]. Another common method used involves manufacture of matrix tablets using gel forming 
agents [162].  
Polymer blends are utilized to improve formulation characteristics, release profiles or to 
stabilize formulations. These blends can also be used to achieve tailored release profiles by using 
appropriate concentrations of water soluble and insoluble polymers [163, 164]. Prodduturi et al 
utilized a blend of HPC and PEO polymer blends to improve physico-mechanical properties of 
Clotrimazole films for transmucosal delivery [51]. Kalivoda utilized a polymer blend to stabilize 
Fenofibrate recrystallization from HME matrices without effecting the release profiles [165]. 
Polymer blends have also been used as targeted delivery systems, to deliver active ingredients to 
the lower intestine [166]. Another application involves miscible polymer blends to tailor release 
dependent upon time constituting chrono therapeutics [167].  
Traditional methods such as, film coating, cannot be effectively used to manufacture 
coating mixtures with polymer blends due to many issues related with such a blend [163]. They 
suffer from drawbacks such as requirement of appropriate solvent that can dissolve all of the 
polymers and also a possibility of flocculation in aqueous dispersions prior to coating [163]. 
HME is a non-solvent continuous process that can be effectively utilized to homogenously mix 
polymers and drugs into a single matrix. The intense mixing operation results in single phase 
system that can hold its integrity even on breaking or crushing, and address issues with film 
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coated tablets. HME polymer blends can also be used to maintain physical and chemical stability 
of the active in addition to imparting mechanical strength.  
This research has attempted to evaluate the advantages of polymer blends to control the 
release of a soluble drug. Hot melt extrusion was utilized as a processing technique due to its 
inherent advantages compared to traditional coating methods. A preliminary evaluation was 
performed utilizing a hot melt casting method and formulation compositions were established. 
Homogenous distribution of polymers was confirmed using a chemical imaging and in vitro 
release studies. Stability assessment was also performed on the films. Higher molecular weight 
Polyethylene oxide polymers have been utilized as rate controlling or modifying agents in HME, 
whereas lower grades such POLYOX™ N10 have been used to enhance solubility, due to its 
hydrophilic character and also to act as plasticizers[45]. In this study PEO was used as a matrix 
former and as a control formulation for CLPM release from such matrices.  
5.3. Materials  
Chlorpheniramine maleate (CLPM) was purchased from Spectrum chemicals (769 Jersey 
Ave. New Brunswick, NJ,). Klucel™ Hydroxypropylcellulose EF polymer (HPC) was obtained 
as a gift sample from Ashland Aqualon functional ingredients (Wilmington, DW); Eudragit 
RSPO (RSPO) was obtained as a gift sample from Evonik Degussa Corporation (379 Interpace 
Parkway, Parsippany, NJ 07054), POLYOX™ N10 was obtained from Dow pharmaceutical 
ingredients. The chemicals used were of analytical grade and obtained from either Fisher 
scientific or Spectrum chemicals. 
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5.4. Methods 
5.4.1. Thermal Characterization 
 Pyris 1 Thermogravimetric analyzer (TGA) controlled Pyris manager software 
(PerkinElmer Life and Analytical Sciences, 719 Bridgeport Ave., Connecticut, USA) was used to 
perform thermogravimetric analysis of samples. Drug and excipients were evaluated for thermal 
stability at high temperatures. 3-4 mg. of the sample was weighed and heated from 25°C to 
200°C at 10°C/min heating rate under an atmosphere of nitrogen. Loss in weight as a measure of 
change in temperature was plotted using Pyris software to generate thermograms. 
 Differential scanning colorimetry (DSC) was performed to detect crystallization changes 
occurring in the drug. A Perkin Elmer Hyper Differential scanning colorimeter (DSC) (Perkin 
Elmer Life and Analytical Sciences, 710 Bridgeport Ave., Connecticut, USA) was used to 
analyze the samples. Thermograms were generated by analyzing 2-3 mg. of the sample in an 
aluminum pan and heated from 20˚C to 200˚C at a linear heating rate of 10˚C/min. Endothermic 
onset and peak temperature at melting were calculated from the software.  A second scan, after 
cooling, was performed to evaluate recrystallization of CLPM utilizing similar testing 
conditions. Pyris manager software was used to control the instrument and analyze the data 
generated. Stability samples were also evaluated at different time points for crystallinity. 
 Polymer-drug miscibility studies were performed on two component mixtures of drug 
(10% to 30%) and polymers Eudragit
®
 RSPO or POLYOX™ N10 or Klucel™ EF. A second 
heating step was utilized to evaluate for crystallinity of CLPM. Extruded systems were also 
evaluated utilizing DSC.  
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5.4.2. Solubility parameters 
 Hansens 3d solubility parameters for CLPM and the polymers were calculated from their 
chemical structures using Molecular Modeling Pro™ software (Fairfield, CA) or referenced from 
the literature. The solubility parameters (δt), account for Hydrogen bonding δh, polar interactions 
δp, and dispersive forces δd and can be used to estimate miscibility between polymers and drug.   
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5.4.3. Formulation Composition 
 Formulation composition was designed keeping the drug concentration constant at 10% 
loading. PEO was used as a base polymer and its concentration was adjusted to accommodate the 
controlled release polymers. Eudragit
®
 RSPO and Klucel
®
 EF (HPC) polymers were utilized as 
release modifying agents to control the dissolution of CLPM. Formulations C1, C2 and C3 were 
used as control formulations. HPC concentration was altered at 10%, 20%, 30% and 55% 
keeping the concentration of the RSPO constant at 25% in C5, C7, C9, & C11 formulations 
respectively. Similarly, RSPO concentration was varied at 15%, 25%, 35% and 55% keeping the 
concentration of HPC at 20% in formulations C4, C7, C8 & C10 respectively. 
 
TABLE: 1 
Formulations 
C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 
Drug 10 10 10 10 10 10 10 10 10 10 10 
Eudragit
®
 
RSPO 
- 25 - 15 25 
25 
(RLPO) 
25 35 25 55 25 
Klucel™ EF - - 20 20 10 20 20 20 30 20 55 
PEO 87.8 62.8 67.8 52.8 52.8 42.8 42.8 32.8 32.8 12.8 12.8 
Antioxidants 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 
Table: 5- 1. Formulation composition of films 
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5.4.4. Hot Melt Casting method for films 
 A hot melt cast (HMC) method was utilized to manufacture films as a preliminary 
screening method. Blends were prepared as per Table 1 and mixed uniformly in a mortar and 
pestle. Weighed samples of mixtures equivalent to 50 mg. drug were weighed, dispersed into a 
heated dye placed over a brass plate, compressed and melted at 140° to 160°C for a period of 10 
minutes. In vitro release and content uniformity studies were performed on patches utilizing an 
HPLC method. 
5.4.5. Hot Melt Extrusion 
 Polymers and the drug were mixed in a V-cone blender for ten minutes and samples 
analyzed for drug content uniformity. The blended material was extruded on a 
ThermoScientific
®
 16mm co-rotating twin screw extruder utilizing a flex lip die to yield films. 
The extruded films were conveyed onto a chill roll to cool and collected in nitrogen filled plastic 
bags. The temperature profile of the barrel was maintained from 80°C to 130°C and 50rpm speed 
was used. Patches were cut from different sections of the films were evaluated for post extrusion 
content and content uniformity.  
5.4.6. HPLC analysis 
 Chemical analysis of samples was performed on a Waters HPLC and Empower software 
was used to analyze the data. The HPLC consisted of a Water 600 controlled binary pump, 
Waters 2489 UV/detector and Waters 717plus autosampler (Waters Technologies Corporation, 
34 Maple St, Miliford MA0157). A Waters Symmetry shield C18, 250mmX4.6, 5 μm particle 
size reverse phase column was used as a stationary phase running a mobile phase constituting 
104 
 
55:45 (%v/v) Methanol: 20 mMol. pH 4 buffer. The UV detector was set at 256nm wavelength. 
Samples for content analysis were analyzed by dissolving weighed samples in 20ml. of 
Methanol, filtered and injected at a 20μl injection volume.   
5.4.7. Particle Size Distribution of Polymers 
 The particle size analysis of the polymers was performed utilizing sieve analysis as per 
the method stated in USP 31. USP standard sieves 25, 35, 40, 50, 70, 80 and 100 were utilized. 
Particle size evaluation was performed to evaluate any demixing of blends in the extruder.  
5.4.8. Near Infrared Chemical Imaging spectroscopy 
Near infra-red chemical images (NI-CI) of HME films were collected on a Sapphire IM 
NIR Spectral Imaging System (Spectral Dimensions, Inc., Olney, MD). The imaging system 
consists of a liquid crystal tunable filter (LCTF) coupled with a NIR sensitive focal plane array 
(FPA) detector. The NIR light reflected (via diffuse reflectance) from the samples to the detector, 
was passed through a LCTF, and was imaged onto the indium-gallium-arsenide focal plane array 
with 256×320 pixels. Images were recorded from the 1400 to 2450nm wavelength at 10nm 
intervals (105 frames). Images were analyzed by ISysIM software (Spectral Dimensions, Inc., 
Olney, MD), each spectrum in the corrected reflectance (R) data cube was converted to 
absorbance by calculating the logarithm of the inverse of the reflectance (log(1/R)). Each 
spectrum in the absorbance cube was further differentiated with the Savitzky–Golay second 
derivative filter with a length of 11 points (100 nm) and a third polynomial order. Pure polymers 
RSPO, HPC, PEO and the drug CLPM were used to construct the library.  
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5.4.9.1. In vitro Release studies and Release mechanisms 
 In vitro release studies were performed using a Hanson SR8+ dissolution test system 
according to USP 31 apparatus 5, paddle over disk method. Dissolution testing was performed 
using 500 ml. pH 6.8 buffer as a dissolution media maintained at 37°C with the paddle rotation 
speed set at 100 rpm. Patches equivalent to 50 mg. drug were cut from extruded films. HMC 
patches were prepared as single units and hence were used as such.  
Data obtained from in vitro release studies was fit to different release models to evaluate 
release mechanism involved. First order, zero order, Higuchi, and Korsemeyer Peppas models 
were utilized. Higuchi’s matrix release model was used to calculate time taken for 80% (T80%) 
and 50% (T50%) drug release from the linear section of the release data. Data points 
corresponding to a correlation value of 0.99 were used for calculations. Coefficient of ‘n’ was 
calculated from equation 4; n=0.45, 0.45<n<0.89 and 0.89<n<1.0 relate to Fickian diffusion, 
non-Fickian diffusion and zero order transport, respectively. A high intercept value k for a 
Koresmeyer fit may suggest a burst drug release from the matrix. The following equations were 
utilized to model the release. 
 
Zero order     (
  
   
)                      -------Equation 5-1 
First order         (
  
   
)  
  
     
  -       ---------Equation 5-2 
Higuchi matrix model      √            ---------Equation 5-3 
Koresmeyer peppas model     (
  
   
)             ---------Equation 5-4 
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5.4.9.2. Statistical analysis 
 The effect of concentration and type of polymer on the release represented by T80% and 
T50% values were fit using JMP 9.0.2 (2010 SAS Institute Inc.) software to understand 
correlation. A surface response curve and P values were calculated to evaluate effect of each 
parameter on the responses. 
5.4.11. Stability testing 
 Films were stored at 25°C/60%RH and 40°C/75%RH for a period of six months and 
evaluated for drug content and crystallinity utilizing a DSC instrument. In vitro release testing of 
C7 formulation were performed on films stored at 4°C, 25°C/60%RH and 40°C/75%RH at 0 and 
3 months duration. Similarity factor was calculated to compare the release profiles. A calculated 
similarity factor of 50 or above is considered to be similar profiles and below as dissimilar. 
5.4.12 Powder X-ray diffraction   
 Powder X-ray diffraction (XRD) studies were performed on a D-8 Advance X-ray 
diffractometer (Bruker AXS) equipped with a SolX detector and DiffracPlus
®
 software. The 
generator voltage and current were set at 40KV and 30mA, respectively. The samples were 
scanned from a range of 10° to 40°, 2Θ values at 0.05° ramp and 3 sec/step.  
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5.5. RESULTS AND DISCUSSION 
5.5.1 Thermal Analysis 
Thermal degradation was not observed for any of the polymers utilized however, CLPM 
exhibited weight loss at around 200°C suggesting thermal degradation. Other excipients utilized 
in this study did not show any degradation till 250°C. Extrusion conditions were maintained 
below these temperatures to prevent any thermal degradation of drug or polymer.  
 
 
Figure: 5-1 TGA Thermograms of CLPM, RSPO, HPC, PEO and C7 formulations 
Physical mixture 
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5.5.2. DSC Miscibility studies 
 CLPM is a crystalline compound with a melting point of 137±0.2°C and endotherm onset 
temperature of 137±0.2°C. A crystalline peak of CLPM was observed in physical mixture of 
CLPM with RSPO and HPC in the initial run but was absent in second reheating step. CLPM 
exhibited miscibility with all the polymers utilized and converted to an amorphous form after 
melting. A Glass transition for amorphous RSPO was observed at around 67°C. Experiments 
were carried out at three different drug loads of 10%, 20% and 30% with PEO to understand 
miscibility of PEO and CLPM as an endotherm peak was not observed at 10% drug load. An 
endotherm onset temperature of 110±1°C and melting peak of 129±.0.8°C was  observed at 30% 
drug load, suggesting miscibility [134].  
 
Figure: 5- 2. DSC thermograms of Physical mixture of CLPM at 10% drug load 
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5.5.3. Solubility parameters calculation 
 Solubility parameters have been used to predict the miscibility of drugs and polymers in 
solid dispersions. Components with similar δt values suggest formation of a miscible system as 
the energy of mixing from intramolecular interactions is balanced with the energy from 
intermolecular interactions. Greenhalgh et al demonstrated that components with Δδt < 7Mpa
1/2
 
are likely miscible and  Δδt > 10Mpa
1/2
 to be immiscible [135]. Difference in δt values for drug 
and polymers, and between polymers was less than 7Mpa
1/2
 suggesting that they are miscible 
with each other. Table 5-2 lists the individual values (in bold) and the difference values (Δδ).  
 
Units - 
Mpa
1/2
 
CLPM HPC RSPO PEO (δt=21.7) 
CLPM 22.6 (δt) 1.8 (Δδ) 4.4 (Δδ) 0.9 (Δδ) 
HPC -- 20.8 (δt) 2.6 (Δδ) 0.9 (Δδ) 
RSPO -- -- 18.2 (δt) 3.5 (Δδ) 
PEO -- --- -- 21.7 (δt) 
 
Table: 5-2. Solubility parameter values for CLPM and excipients 
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5.5.4. Hot Melt Casting  
 A hot melt casting (HMC) method was employed as a screening technique prior to the 
extrusion process to evaluate the feasibility and study the effect of polymer blends to render 
control release. Casting methods allow for faster screening of excipients and their effect on 
release profiles, at the same time utilizing very less amount of the drug [168, 169]. However it 
suffers from the drawback that melts are not mixed and hence homogenous distribution of 
components is not as likely as a melt extrudate.  
 Amongst formulations comprising pure polymers N10 (C1) and blends - HPC (C2) and 
RSPO (C3), respectively, RSPO exhibited a pronounced effect on retarding the release (Fig. 5-
3). C7 formulation comprising RSPO 25% and HPC 20% significantly retarded the release in 
comparison to C1, C2 and C3 patches. HPC and RSPO were able to retard the release better 
when used together than when used separately, exhibiting a synergistic effect. An increase in 
concentration levels of RSPO further in formulations C4, C7 and C8 did not result in retarding 
the release any further. A similar trend was observed in HMC films prepared utilizing HPC in 
formulations C5, C7 and C9 formulations.  
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Figure: 5-3. In vitro release comparison of HMC patches C1, C2, C3 (n=3) 
 
Figure: 5-4 In vitro release comparison of HMC films – a. Effect of RSPO concentration  
b. Effect of HPC concentration (HMC films – denoted by ‘M’) 
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As per observations made from HMC studies, C1, C2, C3 and C7 films were extruded 
and compared. HME formulations exhibited a faster release with PEO, in comparison to HPC 
and RSPO polymers. PEO polymers have been used to enhance solubility of poorly soluble 
drugs previously due their hydrophilic character and ability to form solid dispersions [170, 
171]. Also, CLPM converts to an amorphous form resulting in increased solubility. RSPO 
retained its controlled release characteristic. As earlier observed C7 formulation exhibited the 
slowest release among extruded formulations. Overall HME films exhibited faster release in 
comparison to HMC films.  
 
 
Figure: 5-5. In vitro release comparison of HMC and HME films (n=3) 
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5.5.5. Effect of Particle size on Content and release profiles – C7 films 
 HME process involves melting and mixing of drug and excipients in a heated barrel 
brought on by a rotating screw. The agitation provided by the screw elements allows for the 
material to be uniformly mixed, conveyed forward and be discharged through a die. However, 
patches sectioned from extruded films of the same formulation, exhibited deviations in content 
assay and release, and could not be reproduced from one batch to another. An example of 
patches form C7 formulation has been presented in Fig. 5-6. Blend uniformity confirmed by 
analyzing pre- and post-extrusion drug content confirmed uniform distribution of CLPM.  
A possible explanation towards this deviation could be demixing of polymers inside the 
barrel or incomplete mixing of the blends. The EF polymer utilized for these studies was a coarse 
grade with an average particle size above 100 μm and the rest of the polymers, including the 
drug were of lower particle size, below 100 μm Fig. 5-7). This could have resulted in demixing 
or aggregation inside an extruder leading to irreproducible release profiles. Also, HPC melts at a 
higher temperature allowing it to remain as a softened powder and thus improper mixing might 
have occurred within the melt as the rest of the components would be in a molten state. HPC 
matrices undergo a swelling and erosion driven mechanism to release the drug from an enclosed 
matrix. HPC might not have formed a uniform layer around the CLPM resulting in formation of 
channels in the matrix. Similar observations were reported by Verhoeven et al who observed 
unpredicted release with coarser grade of Xanthan gum [172] . All of the polymers were sieved 
to a standard particle size closest to the drug, and extruded in two different batches. The profiles 
were identical to each other as per similarity factor values proving the hypothesis. In addition 
C7-EFX films manufactured using sieved polymers and EXF, finer grade of HPC EF, also 
exhibited identical profiles.  
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Figure: 5-6. In vitro release profiles of C7 HME Formulation utilizing un-sieved polymers 
 
Figure: 5-7. Particle Size analysis of polymers used to manufacture C7 formulation 
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5.5.6. Near Infrared Chemical Imaging  
 Near IR chemical imaging allows for spatial recording in addition to spectral assessment 
of a sample. Spatial recording can be used to map distribution of individual components on the 
surface by comparing it with pure compounds [173].  Images were generated with the contrast 
depending upon the absorption of a particular wave length characteristic to the drug or polymer. 
Analysis was performed as a qualitative assessment alone, though this technique can also be used 
for qualitative assessment.  
Images obtained were consistent with the dissolution profiles and drug content analysis 
data, suggesting a homogenous distribution of all the components in the matrix. C7-EF (sieved 
polymers) and C7-EFX formulations prepared using Klucel
®
 EF and Klucel
®
 EXF (fine grade 
HPC), respectively, exhibited similar distribution of drug and polymers. CLPM was 
demonstrated to be uniformly distributed in all of the films (Fig.5-8). The C11 film manufactured 
using RSPO at 55% concentration and unsieved EF polymer exhibited segregation and formed a 
continuous phase as seen in Figure 5-8b. These films exhibited rapid release initially due to 
formation of channels in the matrix but later on exhibited sustained release. As per these 
observations all formulations were manufactured using sieved polymers. 
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Figure: 5-8. NICI images of films with distributions based on a) CLPM, b) HPC, c) RSPO 
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5.5.7. In vitro release studies – HME films  
Hydrophilic polymer matrices during dissolution undergo hydration forming a viscous gel 
that continuous to erode releasing the drug. The release is controlled by the extent of polymer 
swelling, polymer relaxation, diffusion through the gel layer and polymer erosion [174]. The rate 
at which this process occurs is dependent upon the molecular weight and chain length of the 
polymer. HPC polymers undergo a similar swelling and erosion based mechanism to release the 
drug [50]. Prodduturi et al  utilized different molecular weight grades of HPC to obtain control 
release of a poorly soluble drug [37]. 
Eudragit RSPO is a hydrophobic acrylic polymer which on exposure to water swells and 
forms a gel matrix. This property increases the diffusional path length a drug molecule has to 
travel to enter the dissolution media and thus retards the release of the drug. The quaternary 
ammonium components undergo solubilization creating channels that allow the drug to diffuse 
into the dissolution media[175]. Higher concentration of these polymers creates a more viscous 
gel that increases the tortuosity and slows the release of the active.  
Addition of HPC, in the C7 formulation resulted in a delayed release with T50% and T80% 
values of 0.75 and 2.2 Hr., respectively. Hydrophilic polymers PEO and HPC dissolve on contact 
with the dissolution media, forming channels in the matrix resulting in higher T50% values. As 
the polymers hydrated further during dissolution, retarded release characterized by higher T80% 
values was observed. RSPO was able to prevent erosion of HPC matrix and by forming a gel. 
HPC might have created a tortuous path for by occupying channels in the RSPO gel. Both the 
polymers work synergistically, effectively preventing erosion and increasing diffusional paths, in 
retarding the release. 
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Drug release was reduced when RSPO and HPC were used simultaneously in C7 formulation 
and were similar to observations made from the hot melt cast films. However and increase in 
concentration of RSPO did not result  in a significant difference in C2, C4, and C7 formulations 
based on f2 values as the release profiles were almost similar (f2>50). Increase in RSPO levels 
from 25% to 35% and 55% resulted in significant retarding of release in formulations C7, C8, 
and C10 respectively (f2<50). Effect was more prominent in T80% release suggesting the time 
taken for the polymers to undergo hydration and gelling phenomena in altering release.  
 
 
Figure: 5-9. In vitro release profiles of HME films – Effect of RSPO concentration (n=3)  
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Figure: 5-10. Time taken for 50% and 80% Release – Effect of RSPO polymer 
 
Addition of RSPO at a 25% concentration to HPC formulations resulted in a prominent 
decrease in release (f2<50). Also, effect of increase in HPC concentration from 10% to 55% 
resulted in a significant decrease of CLPM from the matrices in C3, C5, C7, C9, and C11 
formulations. Decrease in release was more prominent at higher concentrations of RSPO and 
HPC, as observed in C8 to C11 formulations. In the C11 films, a significant effect on T80% 
values was observed. In formulations C8 and C9, time taken for 80% release was 4.8h and 6h, 
respectively. Although it is difficult to understand the release mechanism involved, it can be 
hypothesized that presence of RSPO resulted in a decreased erosion rate of HPC, thereby 
resulting in controlled release.  
Effect of increase in HPC concentration resulted in better retardation of release at higher 
concentrations. Release from C4, C5, C7 formulations followed Fickian trans polymer diffusion 
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as per calculated n-values and fit to Higuchi matrix model, suggesting a dominant effect of 
RSPO in controlling release in these formulations. The additional formulations followed 
anomalous release mechanism resulting from diffusion as well as erosion of the polymers. As 
stated earlier, drug release from RSPO occurs through diffusion from a gel matrix and from HPC 
through a mechanism of swelling and erosion.  
 
 
 
Figure: 5-11. In vitro release profiles of HME films – Effect of HPC 
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Figure: 5-12. Time taken for 50% and 80% Release – Effect of HPC polymer 
 
HPC and PEO being hydrophilic, might have formed channels in RSPO matrix resulting 
in faster release in C5 and C7 formulations initially (T50% values). However as the polymers 
undergo hydration, release slowed down as characterized by higher T80% values. This effect 
was more prominent in C8, C9 and C11 formulations, which took 4.8, 6, and 29 hours 
respectively, to release 80% CLPM (Fig.5-13).  
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Figure: 5-13. In vitro release comparison of HME films manufacutred using HPC+RSPO 
polymers 
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Table: 5-3. Release models and coefficients 
Release 
models 
HME 
films 
C2 
RS 
C3 
HP 
C4 
RS1
5 
C5  
HP1
0 
C7 
RS25 
HP2
0 
C8 
RS3
5 
C9 
HP3
0 
C10 
RS5
5 
C11 
HP5
5 
Higuchi 
diffusion 
Slope 
42.3
5 
72.7
9 
57.4
1 
69.11 37.48 
19.5
5 
14.21 
12.1
7 
14.74 
Regressio
n 0.88 0.98 0.98 0.99 0.95 0.84 0.64 0.79 0.92 
Koresmeye
r 
Intercept   
1.90  1.8 1.67 1.76 1.66 1.7 1.51 1.28 
% Release 
80 - 63 47 57 46 50 33 19 
Slope (n) 
0.53 - 0.56 0.75 0.51 0.42 0.40 0.35 0.51 
T50% Release (in hours) 
0.4 0.1 0.66 1.05 0.75 1.2 1.0 2.4 5 
T80% Release (in hours) 
1.0 0.5 1.5 2.05 2.2 4.8 6.0 27.4 29.0 
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5.5.8. Statistical analysis of release profiles 
 T50% and T80% values obtained from dissolution data were fit to a least squares model 
using JMP software and evaluated. The various parameters such as effect of concentration and 
type of polymers (RSPO, HPC, and PEO) were found to exhibit a significant effect on release 
(p<0.01). A linear relationship was observed with respect to T50% and T80% values to change 
in concentration of RSPO and HPC. A regression coefficient of 91.25 and 94.54 was obtained 
from the actual to the predicted plot suggesting accuracy with which the model could be used to 
predict the effect of concentration of polymers on T50% and T80% values, respectively. Such  
linearity can be utilized to modify concentration of polymers to achieve a targeted release 
profile. All factors–concentration of RSPO, HPC, and PEO were found to exhibit a positive 
effect on retarding the release based on coefficients, with PEO exhibiting the least effect.  HPC 
exhibited a comparatively larger effect on release compared to RSPO.   
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Figure: 5-14. Response surface plot showing effect of concentration of HPC and RSPO on 
T50% release 
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5.5.9. Stability studies 
Films stored at 4°C, 25°C/60%RH and 40°C/75%RH did not exhibit any recrystallization 
or degradation for a period of three months. At the last time point tested, drug concentration 
remained at 97% however an assay was not performed to analyze concentration of degradants as 
CLPM was only used as a model compound. CLPM remained in an amorphous state which was 
confirmed by DSC chromatograms and XRD scans of the films (Fig.5-15). 
 
 
Figure: 5-15. XRD Spectra of C7 films and excipients stored at different storage conditions 
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Figure: 5- 16. DSC thermograms Films -3 month’s stability 
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In vitro release profiles of C7 formulation stored at 4°C, 25°C/60%RH and 40°C/75%RH 
for a period of 3 months exhibited similar release when compared to initial profiles. Calculated f2 
values for films stored at 4°C, 25°C/60%RH and 40°C/75%RH were 79, 54 and 59, respectively, 
suggesting similarity in profiles.  
 
Figure: 5- 17. In vitro release profiles of C7 formulation post storage 
 
 
  
129 
 
5.6. CONCLUSION 
 This study successfully demonstrated that a controlled release film formulation 
for a water soluble drug utilizing polymer blends and hot melt extrusion could be formulated. 
The release mechanisms involved in such a matrix system were studied and its correlation to 
drug release established, paving the way for custom controlled release formulations. Klucel
®
 EF 
and Eudragit
®
 RSPO polymer blends have been demonstrated to modulate a water soluble drug 
release, such that the pharmaceutical scientist may design formulations with desired release 
profile for ones API.  
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CHAPTER VI 
Clotrimazole-Cyclodextrin complex for treatment of vaginal candidiasis 
6.1. ABSTRACT 
The aim of this study was to prepare a Clotrimazole (CT) complex with 2-hydroxypropyl 
beta cyclodextrin (HPCD) to enhance its solubility and release characteristics, for better 
management of vaginal Candidiasis. The CT complex was prepared by a co-precipitation 
method. The phase solubility study was performed to assess the complexation behavior of CT 
with HPCD. The continuous dilution method was used to determine stereochemistry between the 
drug and the complexing agent using Nuclear magnetic resonance spectroscopy. The complex 
was further characterized by DSC, SEM and FTIR methodologies. Complexes were formulated 
into gels using a cold gelation method and characterized for in vitro release and antifungal 
activity. The phase solubility curve was an AL-type, indicating formation of a 1:1 complex 
between the drug and HPCD. The association constant and complexing efficiency were 44.6 M
-1
 
and 0.009, respectively. FTIR and NMR spectra confirmed the stereochemistry of a 1:1 
complexation between CT and HPCD. Also, SEM photomicrographs of the complex showed a 
distinctly different crystalline shape, compared to drug. Additionally, release studies 
demonstrated a sustained release of Clotrimazole from the gel complex for more than 24 h in 
acetate buffer (pH 5.5) with the complex providing improved release. Complexes exhibit better 
fungistatic activity than un-complexed Clotrimazole. 
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6.2. Introduction 
Vulvovaginal Candidiasis (VCD) or Vulvovaginitis is a common vaginal infection 
affecting 75% of women at least once in their lifetime. The affliction is most commonly  caused 
by Candida albicans and hence the name Candidiasis. 10-20% of infections are sometimes 
associated with non-albicans species, of which C.glabrata is the dominant one[176]. It is 
characterized by inflammation of the vagina and vulva, most often caused by bacterial, fungal, or 
parasitic agents. The vaginal ecosystem consists of a healthy interrelationship between micro 
flora, its metabolic products, estrogen and pH levels. This ecosystem is continuously challenged 
by various factors that may sometimes lead to proliferation and colonization of certain micro 
flora. Usage of antibiotics, immunosuppressive conditions such as AIDS, and diabetes mellitus 
may directly or indirectly alter the natural balance leading to Candidiasis. 
VCD can be treated through systemic and topical applications of azole antifungal agents 
of which Clotrimazole (CT) is the most common one. All azoles given orally or topically are 
associated with a dramatic symptom relief in 24-48 hours [177]. CT is an imidazole derivative 
having broad spectrum antifungal activity and has been used extensively in topical therapy for 
treating fungal infections [178]. It is the first line, broad spectrum antifungal agent for 
prophylaxis as well as treatment of oral and vaginal candidiasis [178]. A 7-day topical azole 
therapy is more effective than single dose oral therapy in treating severe infections [179]. 
Clotrimazole is a highly lipophilic in nature (logP 4.1) and has poor aqueous solubility 
(solubility=0.49 mg/L) [180, 181] and slow dissolution in water [180]. It is available in the form 
of creams, vaginal tablets and lotion over the counter in United States. Due to CT’s poor 
solubility, repeated applications are required to maintain a therapeutic concentration. Multiple 
daily doses of conventional formulations result in poor patient compliance. Also, conventional 
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drug delivery systems (exemplified by tablets, creams, gels, pessaries, and foams) suffer from 
poor retention in the vaginal tract, as they are rapidly dislodged in a short time, by the self-
cleansing action of the vaginal tract [182]. Furthermore, the efficacy of these preparations is 
however limited due to their short residence time in the genital tract. 
 
Figure 6-1. Structure of Clotrimazole (CT) 
 
These two problems are compounded in impairing the therapeutic efficacy of 
clotrimazole formulation in the treatment of vulvovaginitis. It is suggested that vaginal therapy 
can be significantly improved if a delivery system can maintain high concentration of the drug at 
the site of administration for a prolonged period. Various methods have been described  to 
improve the solubility of clotrimazole such as using microcapsules[183], thermosensitive 
gels[184], liposomes[185], suspension with hydroxyl-propyl methyl cellulose in 
nanosphere[186] and using hot melt extrusion [51]. Complexation with cyclodextrins and/or its 
derivatives is one of the techniques that can be utilized to increase intrinsic solubility of 
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clotrimazole. Investigators have reported complexation of Clotrimazole with beta-cyclodextrin 
[187, 188], gamma-cyclodextrin [189] which resulted in increased solubility. 
Cyclodextrins (CD) have a wide variety of applications in the pharmaceutical industry 
and have been used as rate controlling agents, solubilizers and taste masking agents. FDA 
considers CD as GRAS (generally regarded as safe) excipients. Modified CD such as 2-
Hydroxypropyl-β-cyclodextrin (HPCD) are considered as Inactive Pharmaceutical Ingredient and 
have also been used in parental formulations in high concentrations. CD derivatives  have been 
effectively utilized to increase the solubility of less water soluble azoles such as Miconazole 
[190], Itraconazole [191], and Sertaconazole [192] and have been very found to be successful . 
 The present study details a formulation approach utilizing the complexation of CT with 
2-Hydroxypropyl β-cyclodextrin to increase its solubility and hence efficacy. Cyclodextrins 
(CD) have been known to enhance solubility by incorporating the drug in the lipophilic core of 
the CD molecule. Complexes were characterized using various methods to confirm type of 
association between HPCD and CT. Thus, formed CT-HPCD complex were formulated as gel 
formulations and evaluated for in vitro release and antifungal evaluation.  
Gels can present several advantages over other formulations like increased 
bioavailability, safety, versatility, being economical  and are also more preferred by women over 
other vaginal applications [193, 194]. That being the reason most of the current research is 
directed at development of bio adhesive gels [195]. Various novel polymers have been designed 
to increase bio adhesiveness but are marked by inadequate activity due to lack of maintenance of 
optimum therapeutic concentration. Bioadhesive misoprostol delivery through the vagina has 
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been found to be more efficacious than when taken orally [195]. Sustained release formulations 
of Miconazole [196] were found to be useful in decreasing the number of applications.   
6.3. Materials 
 Clotrimazole (CT), 2-Hydroxypropyl-β-Cyclodextrin (HPCD), Hydroxy Propyl Methyl 
Cellulose (HPMC), Tween -80, Peirecenet pleated Snake skin dialysis membrane (Thermo 
Fisher Scientific Inc., Rockford, IL USA, distilled water, Acetonitrile.  
6.4. Methods  
6.4.1. HPLC method  
 A modified HPLC method was used for the analytical estimation of Clotrimazole in the 
complexes and the gels. A waters 600 pump with a dual wavelength waters 2489 UV detector 
was used for the HPLC analysis. Phenomenex Luna C18 column with 150x4.60 mm dimensions 
and inner particle size of 5µm was used as a stationary phase. The mobile phase constituted a 
mixture of Acetonitrile (ACN) and pH 5.5 buffer of 50 mM strength at a ratio of 65:35. UV 
detector was set at 210 nm wavelength and Empower software was used to analyze the 
chromatograms. The gels were analyzed by dissolving them in 50:50, ACN: Water mixture and 
then filtered using a 0.45 μ filter. The dissolution samples were centrifuged to remove any 
particulate matter, filtered using a 0.45µm filter and injected into the column. All the standards 
and samples were injected at 20 µl volume. 
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6.4.2. Phase Solubility Studies  
The phase solubility studies of CT were performed using shake flask method described 
by Higuchi and Connors[101]. Excess of drug was added to different known concentrations of 
HPCD and allowed to equilibrate. Concentrations ranging from 0 to 50 mM, in increments of 5, 
were prepared in glass vials using double distilled water. The vials were kept under constant 
shaking at 70 rpm for 7 days at 25ºC. Excess drug allowed for saturation equilibrium to be 
reached. After 7 days, drug solutions were collected, filtered and the supernatant analyzed using 
HPLC for amount of CT dissolved.  
6.4.3. Characterization of Complexes 
 A 25 mM solution of CT and HPCD were prepared by dissolving in Ethanol and let to 
equilibrate for 7 days. Thus obtained solution was filtered and then dried using a vacuum dryer at 
30º-40ºC for 24 h. The formed complex was then characterized using different techniques such 
as Differential Scanning Calorimetry (DSC), Nuclear Magnetic Resonance Spectroscopy 
(NMR), Fourier Transform Infra-Red Spectroscopy (FTIR), X-ray diffraction (XRD) and 
Scanning electron Microscopy (SEM). 
 Complexes were also prepared by physical mixing, kneading methods which employed 
slight amount of solvent to make a slurry and solvent evaporation or co-precipitation method.  
6.4.3.1. Differential Scanning Colorimetry   
 A Perkin Elmer Hyper Differential Scanning Calorimetry was used to analyze the CT, 
HPCD and CT-HPCD complexes. The samples (n=3) were hermetically sealed in aluminum 
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pans and heated over a range from 25º C to 250º C at 10ºC min
-1 
. The obtained spectra were 
analyzed using Pyris manager software.  
6.4.3.2. Fourier Transform Infrared Spectroscopy (FTIR)  
 Infra-red spectroscopy was performed on a Perkin Elmer FTIR- Paragon 500 
spectrometer and the scans were analyzed using Spectrum Ver. 5.0.2 software. The CT, HPβCD, 
and CT-HPCD complex were analyzed by incorporating them with KBr in a ratio of 1:100 and 
compressing them as pellets. The pellets were scanned from 600 to 4000 cm
-1
 wave number eight 
times and spectrum averaged to reduce the noise.   
6.4.3.3. Nuclear Magnetic Resonance Spectroscopy (NMR) 
 A Bruker AV 400MHz Nuclear magnetic spectrometer having a 3mm nalorac dual proton 
optimized probe and running on topspin 2.0 software was used to perform NMR analysis. Pure 
CT, HPCD and the mixtures of two in different mole fractions at 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8 
and 0.9 were dissolved in deuterated dimethyl Sulfoxide and left to equilibrate overnight. 
Samples of 600 μl volumes were then taken in 3mm NMR glass tubes and analyzed. The peak of 
DMSO was taken as a reference peak. Mestrenova software was utilized to analyze the data. 
6.4.3.4. Powder X-ray Diffractions studies 
 Powder X-ray diffraction (XRD) studies were performed on a D-8 Advance X-ray 
diffractometer (Bruker AXS) equipped with a SolX detector and running DiffracPlus
®
 software. 
The generator voltage and current were set to 40KV and 30mA, respectively. The samples were 
scanned from 15° to 40°, 2Θ values with 0.05° ramp at 3 sec/step. Pure components as well as 
complexes manufactured using different methods were evaluated.  
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6.4.3.5. Scanning Electron microscopy 
 Scanning Electron Microscope (SEM) was used to study surface morphology of CT, 
HPCD and that of complexes. Samples were sputter coated with gold using a Hummer
®
 6.2 
sputtering system (Anatech LTD, Springfield, VA) in a high vacuum evaporator. A JEOL JSM-
5600 scanning electron microscope operating at an accelerating voltage of 10kV was used for 
imaging. Samples were mounted on adhesive carbon pads placed on aluminum stubs prior to 
sputter coating. 
6.4.4.1. Preparation of Cyclodextrin Complexes 
 With the data obtained from the Phase solubility studies a 25 mM solution of HPCD was 
prepared in deionized water and allowed to equilibrate with excess drug at 25ºC at 75rpm for 7 
days. A clear solution thus formed was then freeze dried to obtain the CT: HPCD complex which 
was utilized to prepare gel formulations.  
6.4.4.2. Formulation of Gel 
  The gel was prepared by dissolving HPMC in double distilled water to achieve a targeted 
concentration of 1%. The gel was allowed to swell overnight and the swollen matrix was used to 
formulate CT and CT- HPCD complex gels, Gel A and Gel B respectively. A targeted drug 
concentration of 10% CT was used for both the gels. CT due to its low solubility was first 
dissolved in a 50:50 mixture of Polyethylene Glycol 400 and Ethanol, and the same was used to 
disperse it in the HPMC gel using a mechanical homogenizer. The drug and complex mixtures 
were mixed using an Unguator
R 
EWR electronic mortar and pestle for 5 minutes until whole of 
the drug or the complex had blended in. The pH of the gels was adjusted to 5.5 using 
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Orthophosphoric acid. Care was taken to avoid formation of any air bubbles in the gels. The so 
formed gels were analyzed for content and stored at 4
o
 C till further studies. 
The content studies were performed using an HPLC method. Extraction procedure was 
optimized and a 50:50 mixture of ACN:Water was used to extract the drug from the gels. Pre-
weighed gel samples were dissolved, sonicated and filtered using a 0.45 micron filter. The 
content was established by averaging the results obtained from three replications.   
6.4.4.3. In vitro Release studies  
 In vitro release studies were performed using a SR8 Plus Dissolution apparatus by 
Hanson Research. A modified Type II basket apparatus was utilized to perform release studies. 
Snakeskin Pleated Dialysis tubing with a cut off molecular weight of 3500 Daltons was used to 
contain 5 grams of the gel A and B, and a nylon thread was used to seal the tubes on both ends. 
Care was taken to check for any leaks or pores in the dialysis membrane. The gels bags were 
then lowered into the basket and fixed to the dissolution apparatus. The release studies were 
performed in replicates of three each. The baskets were rotated at 50rpm speed. The dissolution 
media consisted of degassed 900ml of pH 5.5 buffer maintained at 37ºC with 1% of Tween 80 
added to maintain sink conditions. Samples were collected at intervals of 0.5, 1, 2, 3, 4, 5, 6, 8, 
12, 24, 48, 72 and 96 hours and centrifuged. Supernatants were injected into the HPLC directly 
and analyzed for percent drug release. The dissolution data was fitted to various release models 
to understand the mechanisms involved.  
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6.4.4.4. Antifungal Testing of the Gels 
 Comparative antifungal evaluation of CT and complexed gels was performed utilizing 
cultures of Candida albicans, C.glabrata and C.krusei. 3-5 colonies of each Candida spp. were 
suspended in 0.9% sterile saline solution and the colonies formed were estimated by measuring 
their optical densities at 630 nm. They were then diluted appropriately to yield 1x10
6
 Colony 
Forming Units per ml. (CFU/ml) in a Saboraud Dextrose Broth (SD). 500µl of cell suspensions 
of different species of the Candida were then uniformly spread on SD agar petri plates with a 
sterile swab, covered and left to dry under the hood. Cylindrical wells of ~75µl were made into 
the cultures and equal amount of gels added into them. The cultures where then incubated in an 
incubator for 72 hours at 37
o
C. Appropriate controls were used to assess any antifungal activity 
due to the excipients used. Controls cultures included CT, HPβCD, Amphotericin-B and HPMC 
- dissolved in DMSO. Zone of inhibition, marked by lack of any fungal growth around the wells, 
was used as a measure to compare fungistatic action of the gels.    
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6.5. RESULTS AND DISCUSSION  
6.5.1. Phase Solubility  
 The Phase solubility studies were performed using the shake flask method as described 
by Higuchi and Connors. The concentration of CT dissolved was plotted against the 
concentration of HPCD used. Addition of HPCD resulted in a significant improvement of 
solubility of CT. The graph was an AL type curve with the linear plot having a R
2
 value of 
0.99[197]. This suggested formation of a 1:1 inclusion complex of CT and HPCD. The stability 
constant obtained from the slope K1:1 was 446.5 M
-1
 using the Higuchi and Connors equation.  
K1:1 =   
     
            
          Equation 6-1. 
Where S0 is the intrinsic solubility of CT 
For drugs which have very less water solubility, complexation efficiency (CE) is a better 
standard of stability due to apparent difficulty in estimating intrinsic solubility values So. The 
complexation efficiency obtained was ~0.01 suggesting 1 in 100 molecules undergoes 
complexation and can be effectively utilized to estimate the formulations weight in solid oral 
dosage forms.  
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Figure 6-2. Phase Solubility curve of CT-HPCD in water 
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6.5.1.1. Thermal studies 
 CT is a crystalline drug with a sharp melting point at 145
o
C – which can be clearly seen 
in the DSC spectra as a melting endotherm (Fig. 6-3). The physical mixture had the characteristic 
CT peak at 145
o
C and a broad peak for HPCD due to water loss. Thermogravimetric studies (not 
shown) confirmed water loss for HPCD and a degradation above 240
o
C, suggesting thermal 
degradation of HPCD which was also observed in the DSC thermograms. The DSC spectra of 
the complex was void of any peaks or broad endotherms signaling formation of a thermodynamic 
equilibrium between the drug and the cyclodextrin. CT formed an amorphous complex with 
HPCD[198]. 
 
Figure 6-3. DSC Thermograms of Complex, HPCD, Physical mixture, Clotrimazole 
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6.5.1.2. Fourier Transform Infra-Red spectroscopic analysis (FTIR) 
 The FTIR spectra of the drug, HPCD, Physical mixture and the complex are presented in 
the Figure 6-4. Kneaded product exhibited slight difference in the peaks suggesting 
complexation, which was more prominent in complexes manufactured using solvent evaporation. 
The peaks corresponding to aromatic C-H stretching above 3000 cm
-1
 for pure CT disappeared in 
the complex. The aromatic ring structure characterized by 1465 cm
-1
 and 1457 cm
-1
 wave 
numbers, disappeared and reappeared as a single broad peak at 1457 cm
-1
, similar to an early 
reported spectral change observed in complex of CT [198]. The influence on central pi bonded 
moiety could be seen by disappearance of peaks at 1327 cm
-1
, 1305.46 cm
-1
 and 1262.56 cm
-1
. 
The aromatic regions corresponding to CT, prominent in 600-800 cm
-1
 region were slightly 
influenced in the kneaded product and disappeared completely in the complex indicating 
inclusion of the aromatic ring in the cavity of the HPCD and possible hydrogen bonding[188]. 
C=N and C=C stretching vibrations were observed at 1650 and 1450 cm
-1
, C-Cl stretching at 750 
cm
-1
 in pure CT, disappeared in the complex suggesting the involvement of aromatic ring ‘A’ 
and ‘B’ in the complexation process. Similar results were observed in the NMR spectra.  
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Figure 6-4. FTIR spectra of puree HPCD, Drug, Physical mixture and Complex 
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6.5.1.3. Nuclear Magnetic Resonance Spectroscopic analysis 
  Continuous variation method was employed to establish the stoichiometry of the complex 
using NMR. DMSO Solutions with increasing mole fraction of CT in HPCD were utilized to 
generate NMR spectra. However, because of complex mixtures of modified CD and there 
isomeric forms, assignment could not be performed for all the protons and only those protons 
that exhibited the maximum deviation have been reported. As suggested in the Figure 6-5, H2, 
H4, H8 and H10 protons suggest inclusion of A and B aromatic rings in the CD cavity as these 
exhibit maximum deviation. H2 and H4 imidazole protons exhibited an upward shift suggesting 
their involvement in forming complexes. Similar observations have been reported by Navarro et 
al [199]. These protons correspond to aromatic ring ‘A’ and are similar to observations made 
from FTIR analysis. A downward shift for H10 protons was observed possibly due to 
interactions with the solvent. Relatively small Δδ values suggest a relatively weak association. 
 
Figure 6- 5. Continuous variance plot of Complexed to un-complexed CT 
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6.5.1.4. X-Ray diffraction studies 
 Powder X-ray diffractions studies were perforemd on pure components as well as 
complexes to evaluate changes in crystallinity. Complexes manufactured from various methods 
such as kneading, physical mixing and freeze drying were evaluated. Characterisitcs crystalline 
peaks corresponding to CT were observed at 18, 21, 23, 25.2 and 28-  2Θ values[200, 201] in 
Physical mixtures and pure CT (Fig. 6-5). Freeze dried complexes and to lesser extent, in 
kneaded complexes, peaks corresponding to CT were either missing or decreased suggesting 
conversion of CT to an amorphous form or possible formation of complexes. A decreased 
intensity in physcical mixtures can suggest complexation.   
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Figure 6-6. PXRD images of pure drug, HPBCD, Physical Mixture, Freeze dried and 
Kneaded complex 
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6.5.1.5. Scanning Electron Microscopy (SEM) 
 SEM studies were performed to study the morphology of components before and after 
complexation. HPCD exhibited globular structure and lacked sharp features characteristic of a 
crystalline nature. DSC results also suggested an amorphous nature. CT is a crystalline 
compound and was characterized by sharp needle like crystals. Complexes formed from freeze 
drying process were cubic in nature and exhibited a different structure to either of the 
components suggesting formation of a complex.  
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Figure 6-7. SEM images of HPCD, CT and Complex 
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6.5.2. Dissolution Testing Release Profile 
 The CT-HPCD, Gel B, exhibited a better release profile compared to pure CT gels. After 
92 hours of release the CT released was only 75% compared to a 100% release with the complex 
(Fig. 6-8). The increased release can be related to the solubilization effect of the Cyclodextrin. 
HPCD assists in the solubilization by incorporating the CT molecule in the Lipophillic cavity of 
the CD and imparting a hydrophilic character to the drug molecule. 
 
Table: 6- 1. Release coefficients obtained from various dissolution models 
  Dissolution Constants Regression  
Zero order  Drug 0.007 0.996 
 Cmplx 0.011 0.946 
First order Drug 0.013 0.853 
 Cmplx 0.012 0.716 
Higuchi  Drug 0.01 0.968 
 Cmplx 0.01 0.992 
Korsemeyer Peppas Drug 0.63 0.95 
 Cmplx 0.62 0.97 
  
The dissolution data was fit various kinetic models to understand the release mechanism 
involved. The drug release from Gel A (unmodified CT) followed Zero order kinetics with a 
release constant of 0.007. Gel B followed zero order kinetics until first 24 hours then deviated 
from zero order. The dissolution data for the complex Gel gave the best fit for the Higuchi model 
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for release suggesting a controlled release from HPCD. Gel B with HPCD resulted in a higher 
solubility, creating a higher concentration gradient resulting in faster and increased release.  
In order to understand the type of diffusion mechanism involved the release was fit to 
Korsemeyer Peppas equation. A diffusion release exponent ‘n’ obtained from the Korsemeyer 
Peppas equation can be used to understand whether the diffusion is fickian or non fickian.  An 
‘n’ value of 0.5 confirms a Fickian diffusion and a value between 0.5 to 1 is for a non-fickian or 
anomalous diffusion[202]. A diffusional release exponent of 0.6 was obtained for both the gels 
confirming anomalous (non-fickian) diffusion of drug. HPMC helped in maintaining a controlled 
release for both the drug and complex. The hydrophilic polymer surrounds the drug molecule 
and the release occurs when the drug molecule dissolves in the media and diffuses out of the 
matrix. The solubilized drug is thus removed from the external layer by the movement of fresh 
solvent layer resulting in zero order release. HPCD results in increased solubilization of drug, a 
higher concentration gradient and hence faster release. 
 
Figure 6-8. In vitro release studies of Gels from Complexed CT and Pure drug  
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6.5.3. Antifungal Testing  
 The gels were tested for antifungal activity using Candida cultures. Zone of inhibition 
(Zi) was utilized as a measure of efficacy of the gels. The antimycotic activity of CT could be 
seen by the marked absence of fungal growth due to the fungistatic activity of CT in the Zi. 
Amphotericin, HPCD and HPMC gels were utilized as controls to evaluate for antifungal 
activity. None was observed. CT and CT-CD complex showed significant absence of any fungal 
growth compared to Amphotericin B. A considerable decrease in the growth of Candida spp. 
was observed [181]. HPCD resulted in an increased concentration of solubilized CT thus aiding 
its fungistatic action.   
 
Figure 6-9. Antifungal activity of CT in pure and complexed form 
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6.6. Conclusion 
 CT formed a 1:1 complex with HPCD which was confirmed by Phase solubility, DSC, 
FTIR, XRD, NMR and SEM studies. Complexes exhibited a significant improvement in 
solubility and dissolution profiles. Complexed CT gels underwent a complete release in 92 h 
whereas gels with un-complexed CT releasing only 60±1.2% in the same amount of time. 
Antifungal testing was performed using different species of Candida and the zone of inhibition 
was used as measure of efficacy of these gels. Complexed CT exhibited a better fungistatic 
activity compared to pure CT. 
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